The Office of Research on Women’s Health (ORWH) is thrilled to host the 5th Annual Vivian W. Pinn Symposium in partnership with the Foundation for the National Institutes of Health (FNIH). Convened by ORWH each year, this event honors the first full-time director of the office, Dr. Vivian W. Pinn, in recognition of National Women’s Health Week. In line with ORWH’s mission of putting science to work for the health of women, this event serves as a critical forum for experts across sectors to communicate and collaborate for the advancement of women’s health.

This year’s event will focus on illustrating the scientific, societal, and economic opportunities of integrating sex and gender into biomedical research and the power of working together. Sex- and gender-aware research is critical for rigorous science, maximizing returns on research investment, and advancing women’s health. Biomedical research achieves its greatest potential when sex and gender considerations are integrated throughout the enterprise in an end-to-end manner, from laboratory and preclinical investigations, through translational studies and clinical care, leading to better science and innovation. However, despite progress made, consideration of sex and gender influences is inconsistently applied across the biomedical ecosystem, highlighting a need for greater integration.

This event will feature a series of panels and interactive breakout sessions with experts from across diverse sectors of academia, industry, non-profits, private funding, and government to generate discussion of system-wide solutions—driving progress towards a healthier future for everyone.

**SYMPOSIUM GOALS**

1. Create bridges and capacity to work bi-directionally across silos within the scientific enterprise to build a resilient, interconnected network that includes federal and private funders of research, industry and business, journal editors and publishers, professional societies, scientific and health organizations, healthcare providers, researchers, academic institutions, policymakers, and the public.

2. Develop strategies to achieve the integration of sex and gender considerations throughout the biomedical research enterprise.

3. Characterize issues related to the health of women and explore women’s health research, along with public health opportunities from a multidimensional perspective to advance the integration of sex and gender considerations via trans-sector approaches and partnerships.

---

**Agenda at a Glance**

**DAY 1 TUESDAY MAY, 11**

9:00 – 10:00 AM  Explore Virtual Environment and Booths (Self-Guided)

10:00 – 10:30 AM  Welcome and Opening Remarks

10:30 – 11:00 AM  Keynote Address

11:00 AM – 12:00 PM  Panel: Teach 1 Reach 1: Academia’s Roll Call

12:00 – 12:30 PM  Lunch Break

12:30 – 1:30 PM  Panel: Moving Beyond Inclusion to Innovation: The Scientific Opportunity

1:30 – 2:30 PM  Panel: The Lifecycle of Communicating the Science

2:30 – 2:45 PM  Break

2:45 – 3:45 PM  Breakout Session 1: Sector-Specific Perspectives

3:45 – 4:00 PM  Break

4:00 – 5:00 PM  Panel: Backed by Public Demand

4:00 – 4:15 PM  Break

4:15 – 5:15 PM  Readout Reports from the Breakout Sessions

5:15 – 5:30 PM  Wrap-up and Closing

5:30 PM – 6:30 PM  Evening Fireside Chat – A Talk with Dr. Vivian Pinn and Dr. Tony Fauci, America’s Doctor

**DAY 2 WEDNESDAY MAY, 12**

9:00 – 10:00 AM  Explore Virtual Environment and Booths (Self-Guided)

10:00 – 10:15 AM  Welcome and Recap of Day 1

10:15 – 11:15 AM  Panel: Government Agencies Call to Action

11:15 AM – 12:15 PM  Panel: “Putting Skin in the Game”: The Economic Opportunity

12:15 – 1:00 PM  Lunch Break

1:00 – 2:00 PM  Panel: Society’s Promise for Improved Science Culture: The Societal Opportunity

2:00 – 3:00 PM  Breakout Session 2 - The Scientific Enterprise

3:00 – 4:00 PM  Creating Synergistic Partnerships: The Power of Working Together

4:00 – 4:15 PM  Break

4:15 – 5:15 PM  Readout Reports from the Breakout Sessions

5:15 – 5:30 PM  Wrap-up and Closing

5:30 – 6:30 PM  Networking Opportunity

The agenda is listed in Eastern Time.

#5thAnnualVPS | Fifth Annual Vivian Pinn Symposium
Vivian W. Pinn, MD was the first full-time director of the NIH Office of Research on Women’s Health from 1991 and Associate Director of NIH for Women’s Health Research from 1994 until her retirement in 2011 when she was named Senior Scientist Emerita at the NIH Fogarty International Center. Under her leadership, the new office led the implementation of NIH inclusion policies for women and minorities in clinical research, developed the first and several subsequent strategic plans for women’s health research, and established new research initiatives and career development programs in collaboration with NIH Institutes and Centers. She established and co-chaired the NIH Working Group on Women in Biomedical Careers with the NIH Director. Prior to NIH she was Professor and Chair of the Department of Pathology at Howard University and previously held teaching appointments at Harvard and Tufts Universities. A graduate and former Alumna Trustee of Wellesley College, she earned her M.D. in 1967 from the University of Virginia School of Medicine, the only woman or minority in her class. She received her post-graduate training in Pathology as an NIH Research Fellow at the Massachusetts General Hospital.

Dr. Pinn is a fellow of the American Academy of Arts and Sciences and was elected to the National Academy of Medicine in 1995. She served several terms on the National Academies Committee on Women in Science, Engineering and Medicine and was a member of the National Academies committee that prepared the 2020 report on ‘Promising Practices for Addressing the Underrepresentation of Women in Science, Engineering, and Medicine: Opening Doors.’ She is also a member of the National Academies Roundtable on Black Men and Black Women in Science, Engineering, and Medicine. Dr. Pinn currently serves on the Board of Trustees/Advisors of Thomas Jefferson University, the Sidney Kimmel Cancer Center at Jefferson, Tufts University School of Medicine and the KGI School of Medicine, and holds the position of Professor, Institute for Advanced Discovery & Innovation at the University of South Florida.

Dr. Pinn has received innumerable honors, including 17 Honorary Degrees of Science, Law and Medicine. The University of Virginia (UVA) School of Medicine named one of its four advisory medical student colleges as ‘The Pinn College’; Tufts University School of Medicine in 2011 announced the ‘The Vivian W. Pinn Office of Student Affairs;’ at the time her former medical students dedicated a scholarship in her name. In 2016, UVA announced that the medical research and education building was renamed for her as ‘Pinn Hall.’ And in December 2016, UVA medical school also announced the inaugural Pinn Scholars program to support and recognize mid-level faculty in efforts to take their research in novel directions. She has held leadership positions in many professional organizations, including as the 88th President of the National Medical Association (NMA) and is currently Chair of the NMA Past Presidents Council. Among other recent honors, she received the 2020 American Medical Association’s Distinguished Service Award for her leadership in women’s health as well as the 2020 Association (NMA) and is currently Chair of the NMA Past Presidents Council. Among other recent honors, she received the 2020 American Medical Association’s Distinguished Service Award for her leadership in women’s health as well as the 2020

Dr. Pinn has received innumerable honors, including 17 Honorary Degrees of Science, Law and Medicine. The University of Virginia (UVA) School of Medicine named one of its four advisory medical student colleges as ‘The Pinn College’; Tufts University School of Medicine in 2011 announced the ‘The Vivian W. Pinn Office of Student Affairs;’ at the time her former medical students dedicated a scholarship in her name. In 2016, UVA announced that the medical research and education building was renamed for her as ‘Pinn Hall.’ And in December 2016, UVA medical school also announced the inaugural Pinn Scholars program to support and recognize mid-level faculty in efforts to take their research in novel directions. She has held leadership positions in many professional organizations, including as the 88th President of the National Medical Association (NMA) and is currently Chair of the NMA Past Presidents Council. Among other recent honors, she received the 2020 American Medical Association’s Distinguished Service Award for her leadership in women’s health as well as the 2020

The mission of NIH, which traces its roots back to 1887, is to seek fundamental knowledge about the nature and behavior of living systems and apply that knowledge to enhance health, lengthen life, and reduce illness and disability. Our annual Vivian W. Pinn Symposium is a part of that process, serving as a vital forum for the thoughtful exchange of critical scientific information and ideas centered on improving the health of women.

This year’s symposium, titled “Integrating Sex and Gender into Biomedical Research as a Path for Better Science and Innovation,” has set several ambitious but necessary goals:

• To illustrate how the continued integration of sex and gender into biomedical research is creating tremendous opportunities for the Nation, not only scientifically but also societally and economically.

• To explore the awesome power of academic, government, nonprofit, for-profit, and business organizations working together to further advance that integration and catalyze innovation.

• To demonstrate how applying a multidimensional perspective to women’s health generates transdisciplinary approaches and partnerships that also can promote integration of sex and gender considerations.

NIH is grateful for the participation of the speakers in the symposium and for their contributions, this week and throughout their careers, to expanding the knowledge base of sex and gender effects. Dr. Pinn is a fellow of the American Academy of Arts and Sciences and was elected to the National Academy of Medicine, the only woman or minority in her class. She received her post-graduate training in Pathology as an NIH Research Fellow at the Massachusetts General Hospital.

Dr. Pinn has received innumerable honors, including 17 Honorary Degrees of Science, Law and Medicine. The University of Virginia (UVA) School of Medicine named one of its four advisory medical student colleges as ‘The Pinn College’; Tufts University School of Medicine in 2011 announced the ‘The Vivian W. Pinn Office of Student Affairs;’ at the time her former medical students dedicated a scholarship in her name. In 2016, UVA announced that the medical research and education building was renamed for her as ‘Pinn Hall.’ And in December 2016, UVA medical school also announced the inaugural Pinn Scholars program to support and recognize mid-level faculty in efforts to take their research in novel directions. She has held leadership positions in many professional organizations, including as the 88th President of the National Medical Association (NMA) and is currently Chair of the NMA Past Presidents Council. Among other recent honors, she received the 2020 American Medical Association’s Distinguished Service Award for her leadership in women’s health as well as the 2020

A message from Francis S. Collins, MD, PhD

Director, National Institutes of Health

It is with great pleasure that I welcome you to the 5th Annual Vivian W. Pinn Symposium, honoring the first full-time Director of the National Institutes of Health (NIH) Office of Research on Women’s Health (ORWH).

The mission of NIH, which traces its roots back to 1887, is to seek fundamental knowledge about the nature and behavior of living systems and apply that knowledge to enhance health, lengthen life, and reduce illness and disability. Our annual Vivian W. Pinn Symposium is a part of that process, serving as a vital forum for the thoughtful exchange of critical scientific information and ideas centered on improving the health of women.

This year’s symposium, titled “Integrating Sex and Gender into Biomedical Research as a Path for Better Science and Innovation,” has set several ambitious but necessary goals:

• To illustrate how the continued integration of sex and gender into biomedical research is creating tremendous opportunities for the Nation, not only scientifically but also societally and economically.

• To explore the awesome power of academic, government, nonprofit, for-profit, and business organizations working together to further advance that integration and catalyze innovation.

• To demonstrate how applying a multidimensional perspective to women’s health generates transdisciplinary approaches and partnerships that also can promote integration of sex and gender considerations.

NIH is grateful for the participation of the speakers in the symposium and for their contributions, this week and throughout their careers, to expanding the knowledge base of sex and gender effects. I commend ORWH and the Foundation for the NIH for bringing together these authorities for what promises to be a productive and informative symposium.

On behalf of NIH, I thank you for your continued support and participation and extend to you my best wishes for a safe, healthy, and productive year.
A message from
Maria C. Freire, PhD
President and Executive Director, Foundation for the National Institutes of Health

Welcome to the 5th Annual Vivian W. Pinn Symposium. For the past four years, NIH’s Office of Research on Women’s Health (ORWH) has hosted this mold-breaking symposium, supporting the important work of ORWH’s first full-time director, the remarkable Dr. Vivian Pinn. The legacy she started—focusing important research on women’s health—will be carried forward through initiatives forged at these convenings.

This year, the Foundation for the National Institutes of Health (FNIH) has the great honor and pleasure of joining with the NIH and the ORWH to co-host this event. Over the next two days, we will examine issues affecting women’s health—through the lenses of biomedical research; scientific and social policy; healthcare disparities based on gender, diversity and economic status; and the boundless potential for innovation when the medical research community widens its focus to one of inclusion and collaboration.

As the FNIH is celebrating 25 exciting and productive years supporting the NIH mission, our 25th Anniversary theme—Science Leads—aligns seamlessly with Dr. Pinn’s vision and with this Symposium. Because of her commitment to letting science lead the way, the world is a better place, not only for women, but for their children, their families and their communities.

We look forward to learning about thrilling new scientific advances that will benefit women – initiatives that provide opportunities to the brightest across all levels of society. Witness the power of partnership between public and private organizations poised to make a difference by including sex and gender considerations into their research.

I would like to thank our co-hosts, our generous sponsors, the panelists and contributors and all of those in attendance for this seminal conference, one that promises a brighter and more equitable future for all.

A message from
Janine Austin Clayton, MD, FARVO
NIH Associate Director for Research on Women’s Health
Director, NIH Office of Research on Women’s Health

I am delighted to welcome you to the 5th Annual Vivian W. Pinn Symposium, the Office of Research on Women’s Health’s signature event, held annually during National Women’s Health Week, honoring our first full-time Director. I would also like to thank the Foundation for the NIH for partnering with us this year to bring you this event.

Dr. Vivian Pinn served as the Director of ORWH from 1991 until 2011. As a champion for women’s health, Dr. Pinn helped to redefine the women’s health field from its beginnings focusing almost exclusively on reproductive health to where it stands today: accounting for the health of women throughout the life course.

The Vivian W. Pinn Symposium began as a way to highlight pressing issues in women’s health, to advance women’s health and sex and gender research at NIH, and to bring together a large, diverse cadre of people dedicated to building better science. This year, the symposium, titled “Integrating Sex and Gender into Biomedical Research as a Path for Better Science and Innovation,” will focus on the scientific, societal, and economic benefits of integrating sex and gender considerations into biomedical research. This important topic goes hand in hand with the NIH Policy on Sex as a Biological Variable, or SABV, which requires NIH-supported investigators to address SABV in research design and analysis.

The SABV policy, now in its sixth year, is essential to good science. Sex differences can have a significant impact on how medicine affects a person, how diseases progress through the body, and even how pain is experienced. While we here at NIH are committed to the SABV policy, we cannot do it alone. Every single one of us here today has a part to play, not just the doctors and researchers. Journal editors, reporters, and publishers of biomedical research also play the important role of increasing the reporting of sex-specific results as they disseminate information about studies and ensuring that implications related to sex and gender are discussed. Expanding the network of the broad range of stakeholders involved in this important endeavor is one of the core reasons that this symposium is held.

I am looking forward to some great discussions and know that with our combined voices and coordinated collaboration, we can ensure that biomedical research will finally lead us to a point where all women receive evidence-based disease prevention and treatment tailored to their own needs, circumstances, and goals.
Keynote Address

Madeleine Dean is a mother, grandmother, attorney, professor, former four-term member of the Pennsylvania House of Representatives, and in her second term of Congress. In Congress, Madeleine represents the Fourth District of Pennsylvania—Berks and Montgomery Counties—and serves on Financial Services Committee, Steering and Policy Committee, is vice chair of the Judiciary Committee, and Co-Chair of the Bipartisan Women’s Caucus. Madeleine has championed progressive priorities like public education, combating addiction, equal rights, access to healthcare, protecting the environment, ethics, criminal justice reform, and gun violence and more.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 – 10:00 AM</td>
<td>Exhibit Hall and Media Room Exploration</td>
</tr>
<tr>
<td>10:00 – 10:30 AM</td>
<td>Welcome and Opening Remarks</td>
</tr>
<tr>
<td>SETTING THE STAGE</td>
<td>Janine Austin Clayton, MD, FARVO, NIH Associate Director for Research on Women’s Health, Director, NIH Office of Research on Women’s Health</td>
</tr>
<tr>
<td>OPENING REMARKS</td>
<td>Maria C. Freire, PhD, President and Executive Director, Foundation for the National Institutes of Health</td>
</tr>
<tr>
<td>10:30 – 11:00 AM</td>
<td>Keynote Address</td>
</tr>
<tr>
<td>11:00 AM – 12:00 PM</td>
<td>Teach 1 Reach 1: Academia’s Roll Call panel</td>
</tr>
<tr>
<td>12:00 – 12:30 PM</td>
<td>Lunch Break</td>
</tr>
</tbody>
</table>

The agenda is listed in Eastern Time.
12:30 – 1:30 PM
Moving Beyond Inclusion to Innovation: The Scientific Opportunity panel
MODERATOR
Yesmean H. Wahdan, MD, Vice President, US Medical Affairs – Women’s Healthcare, Bayer Women’s HealthCare

SPEAKERS
Michelle McMurry-Heath, MD, PhD, President and CEO, Biotechnology Innovation Organization (BIO)
Charlotte D. Owens, MD, FACOG, Therapeutic Area Lead, U.S. Medical Affairs, Women’s Health, AbbVie
Kaveeta P. Vasisht, MD, PharmD, Associate Commissioner for Women’s Health, Director, Office of Women’s Health (OWH), Office of the Commissioner, US Food and Drug Administration (FDA)
Julie M. Zissimopoulos, PhD, Associate Professor, Sol Price School of Public Policy, Senior Fellow, Schaeffer Center for Health Policy and Economics, University of Southern California

1:30 – 2:30 PM
The Lifecycle of Communicating the Science panel
MODERATOR
Jessica Miles, PhD, Senior Publisher, Cell Press/Elsevier

SPEAKERS
Thomas F. Babor, PhD, MPH, Professor of Community Medicine and Public Health, University of Connecticut School of Medicine
Holly Falk-Krzesinski, PhD, Vice President, Research Intelligence & Co-chair, Gender Equity Taskforce, Elsevier
Maira Gano, PhD, Host, BioTech Nation (NPR) and Professor, Bioentrepreneurship, University of San Francisco

2:30 – 2:45 PM
Break

2:45 – 3:45 PM
Breakout Session 1 – Sector-Specific Perspectives
MODERATOR
Heather Bouwman, CEO and Founder of Dot Laboratories, Inc. (DotLab)

SPEAKERS
Kellina Craig-Henderson, PhD, Deputy Assistant Director, Directorate for Social, Behavioral, Economic Sciences (SBES)
Gayle Vaday, PhD, Deputy Director, Congressionally Directed Medical Research Program, U.S. Army Medical Research and Development Command

1. Federal Partners
FACILITATORS
Kellina Craig-Henderson, PhD, Deputy Assistant Director, Directorate for Social, Behavioral, Economic Sciences (SBES)
Gayle Vaday, PhD, Deputy Director, Congressionally Directed Medical Research Program, U.S. Army Medical Research and Development Command

2. Professional Scientific/Medical Societies and Advocacy Organizations
FACILITATORS
Mila N. Becker, JD, Chief Policy Officer, Endocrine Society
Gemima Philippe, MPH, Communication Associate, American Association for the Advancement of Science (AAAS), Center for Public Engagement with Science and Technology

3. Industry and Business/Private Funders
FACILITATORS
Sara Jane Denny, Founder and CEO, Denny-Colton
Hilary S. Gammill, MD, Deputy Director, Maternal, Newborn, and Child Health – Discovery and Tools, Global Health

4. Academic and Research Institutions
FACILITATORS
Elena Rios, MD, MSPH, FACP, President and CEO, National Hispanic Medical Association
Janice L. Werbinski, MD, President, American Medical Women’s Association and Clinical Associate Professor Emerita of OB/Gyn Western Michigan University Homer Stryker School of Medicine

5. Publishers/Journals
FACILITATORS
Nathalie Le Bot, PhD, Chief Life Sciences Editor, Nature Communications, Nature Portfolio
Karla Shepard Rubinger, Vice President, Mary Ann Liebert Inc. and Executive Director, Institute for Professional Education

3:45 – 4:00 PM
Break
DAY 2  
WEDNESDAY, MAY 12, 2021

9:00 – 10:00 AM  
Exhibit Hall and Media Room Exploration

Exhibit Hall and Media Room

10:00 – 10:15 AM  
Welcome and Recap of Day 1

Auditorium

10:15 – 11:15 AM  
Government Agencies Call to Action panel

Auditorium

– MODERATOR
  Jenny Luray, Vice President of Strategy and Communications, Research! America

– SPEAKERS
  Michael Lauer, MD, Deputy Director for Extramural Research, National Institutes of Health
  Rachel Levine, MD, Assistant Secretary for Health, HHS Office of the Secretary
  Alondra Nelson, PhD, Deputy Director for Science and Society for the White House Office of Science and Technology Policy
  Susan Wood, PhD, Research Professor, Department of Health Policy and Management, Milken Institute, George Washington University Advisory Committee on Research on Women's Health (ACRWH)
  Elizabeth Yano, PhD, MSPH, VA Greater Los Angeles Healthcare System Director, VA HSR&D Center for the Study of Healthcare Innovation, Implementation and Policy Director, VA Women's Health Research Network

11:15 AM – 12:15 PM  
“Putting Skin in the Game”: The Economic Opportunity panel

Auditorium

– MODERATOR
  Jennifer Friel Goldstein, BSE, MBA, MB, Managing Partner, Lifesciences and Healthcare Practice, Silicon Valley Bank

– SPEAKERS
  Faz K. Bashir, MD, Lead Venture Investor, Portfolia FemTech Fund I & II
  Robert M. Califf, MD, MACC, Head of Clinical Policy and Strategy for Verily and Google Health, Adjunct Professor, Duke University and Stanford University, Former FDA Deputy Commissioner to Barack Obama
  Anula Jayasuriya, MD, PhD, MBA Founder and Managing Director, EXXclaim Capital; Co-founder Evolvence India Life Science Fund
  Carolee Lee, CEO and Founder, WHAM, TheWHAMreport.org
  Nola Mastersen, MSc, Managing Director, Science Futures LLC

12:15 – 1:00 PM  
Lunch Break

4:00 – 5:00 PM  
Backed by Public Demand panel

Auditorium

– MODERATOR
  Erika Miller, JD, Senior Vice President and Counsel, Cavarocchi – Ruscio – Dennis Associates, LLC

– SPEAKERS
  Chloe E. Bird, PhD, FAHAS, FAANB, Senior Sociologist, RAND Corporation
  Paula A. Johnson, MD, MPH, President, Wellesley College
  Carl V. Hill, PhD, MPH, Chief Diversity, Equity and Inclusion Officer, Alzheimer’s Association
  Sudip S. Parikh, PhD, Chief Executive Officer, Executive Publisher, Science Family of Journals, American Association for the Advancement of Science (AAAS)

5:00 – 5:30 PM  
Wrap Up and Closing

Auditorium

– SPEAKER
  Jamie White, MS, Health Science Strategy and Relations Lead, NIH Office of Research on Women's Health

5:30 – 6:30 PM  
Evening Fireside Chat – A Talk with Dr. Pinn and America’s Doctor, Dr. Fauci

Networking Lounge

– SPEAKERS
  Anthony S. Fauci, MD, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Vivian W. Pinn, MD, Senior Scientist Emerita, Fogarty International Center, National Institutes of Health

– FACILITATOR
  Jamie White, MS, Health Science Strategy and Relations Lead, NIH Office of Research on Women’s Health
3:00 – 4:00 PM  Creating Synergistic Partnerships: The Power of Working Together  
  Auditorium  
  – MODERATOR  
  Kathryn G. Schubert, MPP, President and CEO, Society for Women’s Health Research  
  – SPEAKERS  
  Nakela L. Cook, MD, MPH, Executive Director, Patient-Centered Outcomes Research Institute (PCORI)  
  Joshua Denny, MD, MS, CEO, All of Us Research Program, National Institutes of Health  
  Phuang Khahn Morrow, MD, Vice President of Global Development and Therapeutic Area Head of Hematology, Amgen  
  Janet Stovall, Senior Client Strategist, NeuroLeadership Institute

4:00 – 4:15 PM  Break

4:15 – 5:15 PM  Readout Reports for the Breakout Sessions  
  – SPEAKERS  
  1.  Federal Partners  
     Gayle Vaday, PhD, Congressionally Directed Medical Research Program, U.S. Army Medical Research and Development Command, Deputy Director  
  2.  Professional Scientific/Medical Societies and Advocacy Organizations  
     Mila N. Becker, JD, Chief Policy Officer, Endocrine Society  
  3.  Industry and Business/Private Funders  
     Sara Jane Demy, Founder and CEO, Demy-Colton  
  4.  Academic and Research Institutions  
     Janice L. Werbinski, MD, President, American Medical Women’s Association and Clinical Associate Professor Emerita of OBGyn Western Michigan University Homer Stryker School of Medicine  
  5.  Publishers/Journals  
     Nathalie Le Bot, PhD, Chief Life Sciences Editor, Nature Communications, Nature Portfolio

5:15 – 5:30 PM  Wrap-up and Closing  
  – Auditorium  
  – SPEAKER  
  Vivian W. Pinn, MD, Senior Scientist Emerita, Fogarty International Center, National Institutes of Health

5:30 – 6:30 PM  Networking Opportunity  
  – Networking Lounge
At Myovant Sciences, we aspire to redefine care through purpose-driven science, empowering medicines, and transformative advocacy. We believe the first step to progress is understanding the problem. The diseases we are focused on affect millions of women and men, often in their most productive years, and our team is committed to bringing much-needed attention and innovation to these common conditions.

“We are pleased to partner with the FNIH for their upcoming Vivian Pinn Symposium. This conference is closely aligned with Myovant’s goals to redefine care for women by making critical advancements in inclusion of sex and gender in research. We are pleased to join them in bringing recognition to the continued need for new options and innovation in many communities across women’s health.”

JUAN CAMILO ARJONA FERREIRA, MD Chief Medical Officer
She received a B.S. from Xavier University of Louisiana and a Ph.D. from Rice University. Her research interests include screening, diagnosis, early intervention, and treatment evaluation, as well as alcohol and drug policy. He is Editor-in-Chief of the Journal of Studies on Alcohol and Drugs. He is co-chair of the Gender Policy Committee of the European Association of Science Editors, Association’s Dr. Nathan Davis Awards Committee’s Promise for Improved Science Culture: The Societal Opportunity panel; Steering Committee Member; Panelist – The Lifecycle of Communicating the Science panel; Advisor to Springboard Enterprises (www.sb.co) Life Sciences Council.

Mila N. Becker, Esq., Chief Policy Officer, Endocrine Society. Mila oversees the Government & Public Affairs Department, which manages the Society’s public policy agenda and advocacy efforts. Her work includes developing strategies to improve policies that will impact research funding and policies, clinician payment, and quality of care. She has worked extensively on women’s health and women’s health research issues and on global advocacy related to endocrine disrupting chemicals. She also serves as liaison to the Clinical Affairs, Research Affairs, and Advocacy & Public Outreach Core Committees and is a Board member of the Coalition for Health Funding. For the last 20 years, Mila has worked in government relations for non-profit health related organizations. Prior to joining the Endocrine Society in July 2013, she spent ten years at the American Society of Hematology as the Senior Director for Government Relations, Practice, & Scientific Affairs. Before that, she worked as a senior lobbyist for AARP where she was responsible for prescription drug and other high priority health issues, and she was Director of Public Policy for Prevention, a coalition dedicated to disease prevention and health promotion. She holds a B.A in political science from Northwestern University and a J.D from Georgetown University Law School.

Arthur P. Arnold, Ph.D. is the Rockefeller University studies mechanisms causing sex differences in phenotype and disease. His research has included the discovery of large structural sexual dimorphisms in the CNS, development of several animal models for studying sex differences, and studies of mechanisms by which sex-biasing factors operate, including sex hormones and microRNAs. His lab is also interested in the role of gender and sex differences in age-related disease. His current research is focused on the study of sex differences in disease, cellular and tissue engineering, and the role of race/ethnicity and gender in science and engineering. Dr. Arnold is a member of The Rockefeller University President’s Council, a member of the National Academy of Sciences, a member of the National Academy of Engineering, and a member of the American Academy of Arts and Sciences.

Arthur P. Arnold, Ph.D., is the Rockefeller University studies mechanisms causing sex differences in phenotype and disease. His research has included the discovery of large structural sexual dimorphisms in the CNS, development of several animal models for studying sex differences, and studies of mechanisms by which sex-biasing factors operate, including sex hormones and microRNAs. His lab is also interested in the role of gender and sex differences in age-related disease. His current research is focused on the study of sex differences in disease, cellular and tissue engineering, and the role of race/ethnicity and gender in science and engineering. Dr. Arnold is a member of The Rockefeller University President’s Council, a member of the National Academy of Sciences, a member of the National Academy of Engineering, and a member of the American Academy of Arts and Sciences.

Institute for Medical and Biological Engineering (AIMBE) and the Biomedical Engineering Society (BMES). She is past-President of the AAAS, and is a Fellow of AAAS, the American Institute of Chemical Engineers (AIChE), the American Academy of Arts and Sciences. She is president-elect of the American Association for the Advancement of Science (AAAS), and is a Fellow of AAAS, the American Institute of Physics (AIP), and the American Society for Cell Biology (ASCB). She is a member of the National Academy of Sciences, the National Academy of Engineering, and the American Academy of Arts and Sciences. She is a member of the American Academy for the Advancement of Science (AAAS), and is a Fellow of AAAS, the American Institute of Physics (AIP), and the American Society for Cell Biology (ASCB). She is a member of the National Academy of Sciences, the National Academy of Engineering, and the American Academy of Arts and Sciences. She is president-elect of the American Association for the Advancement of Science (AAAS), and is a Fellow of AAAS, the American Institute of Physics (AIP), and the American Society for Cell Biology (ASCB). She is a member of the National Academy of Sciences, the National Academy of Engineering, and the American Academy of Arts and Sciences.
CHLOE E. BIRD, PHD, FAAAS, FAAHB
Steering Committee Member; Co-chair and Panelist – Backed by Public Demand panel

Chloe E. Bird, Ph.D., FAAAS, FAHAHB, is a senior sociologist at RAND, where she studies women’s health and determinants of differences in men’s and women’s health and health care. Her current work examines the return on investment of increasing funding for research on the health of women and assesses gaps in women’s health care and ways to improve and integrate women’s reproductive health care into their care across the life course to reduce cardiovascular risk, improve outcomes, and address racial disparities. Her recent projects include a study assessing gender disparities in quality of care among Medicare Advantage beneficiaries, in her book Gender and Health: The Effects of Constrained Choice and Social Policies (Cambridge University Press, 2008), she coauthored Patricia P. Rieker explore how policymakers and other stakeholders shape individuals’ opportunities to pursue a healthy life. They emphasize the need for research that informs stakeholders’ decisions in order to improve women’s health and reduce disparities.

Dr. Bird has served as a senior advisor in the National Institutes of Health’s Office for Research on Women’s Health and as editor-in-chief of the journal Women's Health Issues, where she is now associate editor. She received the 2020 William Foote Whyte career award from American Sociological Association Section on Sociology and Public Sociology for her work on the health of women, and a 2015 Leadership Award, California Department of Managed Health Care, for her work on women’s cardiovascular outcomes and reducing gender disparities.

Dr. Bird is working to build a donor-funded Women’s Health Research and Policy Center at RAND. She is a Fellow of the American Association for the Advancement of Science and a member of Women of Impact in Science, Engineering, and Medicine: Opening Doors. As Editor-in-Chief of the Proceedings of the National Academy of Sciences, she has authored editorials on race and gender issues in science and is working to increase participation of women and other underrepresented groups on the Editorial Board.

MAY BERENDAUM, PHD
Steering Committee Member; Co-chair and Panelist – The Lifecycle of Communicating the Science panel; Sub-committee Member – Backed by Public Demand panel

May Berendbaum Ph.D. has been on the faculty of the Department of Entomology at the University of Illinois at Urbana-Champaign since 1980, serving as head since 1992 and as Swanlund Chair of Entomology since 1996. Her research, which has produced more than 300 publications, focuses on mechanisms underlying interactions between insects and plants and on incorporating ecological principles into sustainable management practices, testifying twice before Congress on issues relating to pollinator decline. Devoted to teaching and fostering scientific literacy, she has authored numerous magazine articles and six books about insects for the general public. With respect to issues of diversity, equity, and inclusion, at UIUC during her long tenure as department head she has worked to increase the proportion of faculty from underrepresented minority groups to its current level of 51% (including the first two black female faculty members in the School of Integrative Biology). As a member of National Academy of Sciences, she has served as a member of the NASEM Report Review Committee and reviewed several reports on the status of women in science, as a member of the NASEM Committee on Women in Science, Engineering, and Medicine, and as a member of the study committee authoring the 2020 report Promising Promises for Addressing the Underrepresentation of Women in Science, Engineering, and Medicine: Opening Doors. As Editor-in-Chief of the Proceedings of the National Academy of Sciences, she has authored editorials on race and gender issues in science and is working to increase participation of women and other underrepresented groups on the Editorial Board.

HEATHER BOWERMAN
Panelist – Moving Beyond Inclusion to Innovation: The Scientific Opportunity panel

Heather Bowerman is the founder and CEO of Dotlab, a molecular diagnostics company in women's health. Bowerman has been recognized as a TR-35 Global Innovator by the MIT Technology Review, a World Technology Award Finalist for Health & Medicine, and as one of the 100 Most Intriguing Entrepreneurs by Goldman Sachs. She was previously a management consultant at McKinsey & Company in healthcare and technology, an associate in the Obama White House's Office of Science & Technology Policy, and Harvard's nanotechnology teaching fellow. She is a graduate of the UC Berkeley College of Engineering and Harvard University.

Bowerman founded DotLab in 2016 because one of the world’s most prevalent, irreversibly debilitating diseases—that happens to only affect females—lacks sufficient tools for diagnosis, leaving millions undiagnosed or with a significant delay to diagnosis. Dotlab has launched the “EMPOWER” study across the US, one of the largest-ever efforts to evaluate a non-invasive diagnostic tool for endometriosis and the first multi-center, prospective, cohort clinical diagnostic study of its kind. The biology of endometriosis is complicated and poorly understood, and a study like EMPOWER is necessary to bring diagnostic tools to market. Historically, studies of this magnitude have been lacking because women’s health is an underserved market, today representing less than 5% of health research spend.

The EMPOWER Study represents a significant stride for endometriosis and women’s health. Dotlab has been named as an “Amazing Medical Breakthrough” by Reader’s Digest and as one of the “Fierce 15” companies by FierceMedTech.
ANNA MARIE CAUCE, PHD
Steering Committee Member; Subcommittee Member and Moderator – Teach 1 Reach 1: Academia’s Promise
ANNA MARIE CAUCE is the 33rd president of the University of Washington where she has been a member of the faculty since 1998. A graduate of the University of Miami and Yale University, she is a noted scholar on risk and resilience among adolescents. A member of the American Academy of Arts and Sciences, she has received numerous awards for her research as well as the University’s Distinguished Teaching Award. Before becoming president in 2015, she served as Director of Clinical Training in Psychology, as chair of the Departments of American Ethnic Studies and Psychology, as dean of the College of Arts and Sciences and as Provost. In 2008, she played a key role in executing the Moody Promise, a program that has helped more than 10,000 low-income students attend the UW. Since becoming president, Cauce has put a spotlight on the UW’s work in Population Health across the University, launched the University’s Race & Equity Initiative and been a champion for ensuring the UW and public higher education across the country remain accessible and affordable for all students. She is also a strong advocate for women and underrepresented Black, Indigenous, Latinx and other people of color to pursue careers in science, technology, engineering, mathematics, business and health fields. As president, and throughout her tenure, she has worked to advance the University’s mission of serving the public good by focusing on the UW’s impact on the lives of the people in Washington and throughout the world.

ANNE CLAIBORNE, JD, MPH
Manager in the Science in Society Program at the Chan Zuckerberg Initiative. In this role she develops and manages opportunities to enable community, civic, and policy engagement by scientists and to foster an equitable, inclusive, and responsive scientific ecosystem. She also advises on the strategic direction and priorities of the Science in Society program and coordinates diversity, equity, and inclusion efforts across CZI’s Science initiative. Prior to joining CZI in March 2018, she spent eight years as a Senior Program Officer at the National Academies of Sciences, Engineering, and Medicine, where she focused on health sciences policy and ethics relating to clinical research and therapeutics discovery. At the National Academies, she was the responsible staff officer for, among other programs, the Forum on Drug Discovery, Development, and Translation (roundtable director); Mitochondrial ReplacementTechniques: Ethical, Social, and Policy Considerations (study director); Research & Development of Medical Products for Epidemic Response (Hong Kong workshop director); and Sharing Clinical Trial Data: Maximizing Benefits and Minimizing Risk (senior advisor and team lead). Before the National Academies, she was a health care lawyer in private practice at an international law firm. Over the course of her career, she has advised and managed complex, high-stakes health regulatory and biomedical research policy programs across diverse areas, including innovative and emerging biotech, patient-driven research, clinical and translational science, novel biotechnology development collaborations, epidemic disease, and global research and public health capacity-building. She received her J.B. with distinction from Stanford University, where she also served as an editor of the Journal of the California Medical Association. She also edits the Health Law Review, and her MPH from Johns Hopkins Bloomberg School of Public Health.

JANINE AUSTIN CLAYTON, MD, FARVO
Steering Committee Member - Federal Liaison; Speaker - Setting the Stage
JANINE AUSTIN CLAYTON, MD, FARVO, was appointed Associate Director for Research on Women’s Health and Director of the Office of Research on Women’s Health at the National Institutes of Health in 2012. Dr. Clayton has strengthened NIH support for research on disorders, diseases, and conditions that affect women. She is the architect of NIH policy requiring scientists to consider sex as a biological variable across the research spectrum, a part of NIH’s initiative to enhance reproducibility, reliability, and transparency. As co-chair of the NIH Working Group on Women in Biomedical Careers with NIH Director Dr. Francis Collins, Dr. Clayton also leads NIH’s efforts to advance women in science careers. In 2021, Dr. Clayton was elected to the Board of Directors of the American Association for the Advancement of Science (AAAS).

Dr. Clayton was previously the Deputy Clinical Director of the National Eye Institute (NEI). A board-certified ophthalmologist, Dr. Clayton’s research interests include autoimmune ocular diseases and the role of sex and gender in health and disease. Dr. Clayton has a particular interest in ocular inflammation and has identified a novel form of disease associated with premature ovarian insufficiency that affects young women, setting the stage for her commitment to rigorous, thoughtful exploration of the role of sex and gender in health and disease. She is also the author of more than 120 scientific publications, journal articles, and book chapters. Her clinical research has ranged from randomized controlled trials of novel therapies for immune-mediated ocular diseases to studies on the development of digital imaging techniques for the anterior segment.

Dr. Clayton, a native Washingtonian, received her undergraduate degree with honors from Johns Hopkins University and her medical degree from Howard University College of Medicine. She completed a residency in ophthalmology at the Medical College of Virginia. Dr. Clayton completed fellowship training in cornea and external disease at the Wilmer Eye Institute at Johns Hopkins Hospital and in uveitis and ocular immunology at NEI.

Dr. Clayton has received several awards and has been recognized as a leader by her peers. She received the Senior Achievement Award from the American Academy of Ophthalmology, the Board of Directors of the American Academy of Ophthalmology’s first-ever LGBT award as a 2010 Silver Fellow by the Association for Research in Vision and Ophthalmology, and won the European Uveitis Patient Interest Association Clinical Uveitis Research Award in 2010. In 2015, she was awarded the American Medical Women’s Association Lila A. Walls Women’s Health Award and the Wenger Award for Excellence in Public Service. Dr. Clayton was granted the Bernadine Healy Award for Visionary Leadership in Women’s Health in 2016. She was also selected as an honoree for the Woman’s Day Red Dress Awards and the American Medical Association’s Dr. Nathan Davis Awards for Outstanding Government Service in 2017.

FRANCIS S. COLLINS, MD, PHD
Speaker – Opening Remarks
FRANCIS S. COLLINS, MD, PhD was appointed the 16th Director of the National Institutes of Health (NIH) by President Barack Obama and confirmed by the Senate. He was sworn in on August 17, 2009. In 2017, President Donald Trump asked Dr. Collins to continue to serve as the NIH Director. President Joe Biden did the same in 2021. Dr. Collins is the only Presidentially appointed NIH Director to serve more than one administration. In this role, Dr. Collins oversees the work of the largest supporter of biomedical research in the world, spanning the spectrum from basic to clinical research.

Dr. Collins is a physician-geneticist noted for his landmark discoveries of disease genes and his leadership of the international Human Genome Project, which culminated in April 2003 with the completion of a finished sequence of the human DNA instruction book. He served as director of the National Human Genome Research Institute at NIH from 1993-2008.

Dr. Collins is an elected member of both the National Academy of Medicine and the National Academy of Sciences, was awarded the Presidential Medal of Freedom in November 2017, and received the National Medal of Science in 2009. In 2020, he was elected as a Foreign Member of the Royal Society (UK) and was also named the 50th winner of the Templeton Prize, which celebrates scientific and spiritual curiosity.
KELLINA CRAIG-HENDERSON, PHD
Steering Committee Member - Federal Liaison; Facilitator - Federal Partners breakout session

Dr. Kellina M. Craig-Henderson is a former Professor of Psychology who currently serves as the Deputy Assistant Director for the Social, Behavioral and Economic Sciences Directorate of the National Science Foundation (NSF). She previously served as the Deputy Division Director of the Social and Economic Sciences Division of SBE before transitioning into the role of Director for NSF's Tokyo Regional Office.

Before undertaking-fulltime Federal service at NSF, she was promoted to the rank of Full Professor in the Department of Psychology at Howard University.

Dr. Craig-Henderson graduated from Wesleyan University in Connecticut before attending the Master’s Program in the Social Sciences at the University of Chicago where she earned a M.A. Immediately following that she attended Tulane University in New Orleans, Louisiana and earned an M.S. and a Ph.D. in Psychology. She served on the faculty in the Department of Psychology as well as the Afro-American Studies and Research program at the University of Illinois in Champaign Urbana.

This was followed by an appointment in the Psychology Department of California State University Fullerton.

Dr. Craig-Henderson is passionate about broadening the participation of underrepresented groups, and has been involved in a number of national and international activities that share this focus. She has taken on a leadership role in the National Science Foundation to promote the establishment of a new social science funding mechanism that supports evidence-based research on the Science of Broadening Participation. Her efforts have resulted in federal support for research examining issues related to gender parity in STEM, minority participation in work settings as well as a number of other areas.

She has published reports detailing her own empirical research in peer reviewed journals as well as two books on interracial relationships. Her research program includes studies of groups, cross-cultural, gender and race issues, as well as aggression, and epistemic processes. Her work has been supported by a variety of public and private sources including NSF, the Ford Foundation, and the American Psychological Association, and she has presented findings from her research activities at a variety of regional, national, and international research and pedagogical meetings.

SARA JANE DEMY
Steering Committee Member; Co-chair – Moving Beyond Inclusion to Innovation: ‘The Scientific Opportunity panel; Facilitator – Industry and Business/Private Funders breakout session; Subcommittee Member – “Putting Skin in the Game”: The Economic Opportunity panel; Subcommittee Member – Societies’ Promise for Improved Science Culture: The Societal Opportunity panel; Speaker – Readout Reports for the Breakout Sessions

Sara is one of the most influential networkers and connectors in the life sciences industry. As the CEO & Founder of Demy-Colton, a leading life sciences events organizer, she brings more than 22 years of experience launching, developing, and shaping high-profile investor and business development conferences in the healthcare industry. In 2008, Sara founded Demy-Colton, a company dedicated to facilitating growth in life sciences and digital medicine, through the creation of compelling industry conferences and virtual events. She is committed to fostering the support and advancement of entrepreneurs and companies that are focused on bringing innovative new therapies to improve patient lives and care. Sara is a fierce advocate for diversity in all forms and has made a commitment to fostering inclusion in all Demy-Colton events, both in-person and virtual. As one of the founders of Biotech Showcase, she led the movement on calling out “manels,” and made a commitment to ensure gender diversity on all panels, at all events. Prior to founding Demy-Colton, Sara was Vice President for Business Development and Investor Relations at the Biotechnology Innovation Organization (BIO). During her tenure, she led the launch of the BIO CEO & Investor Conference, BIO Investor Forum, BIO Asia, regional investor forums, the Business Forum at BIO’s annual meeting. She expanded BIO-Europe, helped launch BioEurope Spring, and BioEquity, and developed the partnering system that is now an important component of all biopharma business development meetings. Sara was also Director for Foreign Investment at the Empire State Development Corporation, which has a mission of making New York a location of choice for international companies. One of her client relationships was with the Massachusetts Life Sciences Commission. Sara has worked with Beecham that she was introduced to the then nascent biopharma industry and ultimately, BIO. Sara holds a BA in International Relations from the University at Albany.
JOSHUA DENNY, MD, MS
Panelist – Creating Synergistic Partnerships: The Power of Working Together

Josh Denny is the Chief Executive Officer of the National Institutes of Health’s All of Us Research Program. He has been involved in transdisciplinary research from its inception: first as a Member of the initial Scientific Advisory Board of the NIH Clinical Center’s Genomics Medicine Initiative Working Group, which developed the program’s initial scientific blueprint. He led the program’s initial prototyping project and served as the principal investigator for the All of Us Data and Research Center.

As a physician scientist, Josh is deeply committed to improving patient care through the advancement of precision medicine. Before joining the NIH, Josh was a Professor of Biomedical Informatics and Medicine, Director of the Center for Precision Medicine, and Vice President for Personalized Medicine at Vanderbilt University Medical Center. In his roles at VUMC, he was both a practicing internist and a researcher. His research interests include use of electronic health records (EHRs) and genomics to better understand disease and drug response. He also led efforts implementing precision medicine to improve patient outcomes. Josh was a leader in the development of phenotype-wide association studies (PheWAS) and phenotype risk scores. He served as PI for Vanderbilt sites in the Electronic Medical Records and Genomics (eMERGE) Network, Pharmacogenomics Research Network (PGRN), and the Implementing Genomics into Practice (iP2) Network.

He is an elected member of the National Academy of Medicine, the American Society for Clinical Investigation, and the American College of Medical Informatics.

JENNIFER DUCK, JD
Steering Committee Member

Jennifer Duck serves as Vice President of Public Affairs for Novo Nordisk Inc. Prior to joining Novo, Jennifer served as Staff Director and Chief Counsel of the Senate Judiciary Committee for the minority and as Chief of Staff for Senator Diane Feinstein of California. Jennifer spent several years working at Pfizer, Inc. as Vice President of Policy, External Affairs, and Communications.

Her previous government experience included serving as Staff Director and Chief Counsel on the Subcommittee of Terrorism, Technology and Homeland Security of the Senate Judiciary Committee, as well as counsel to Democratic Leader Tom Daschle, counsel for Senator Ted Kennedy on the Senate Health, Education, Labor and Pensions Committee; and, as a Senior Policy Advisor for the Senate Democratic Policy Committee.

Jennifer’s executive branch and state and local government experiences include time in the Clinton Administration at his Department of Labor’s Office of Intergovernmental Affairs where she managed outreach to state and local officials as well as with Congressional Affairs. Jennifer worked on the Obama Presidential Transition with the teams for the Department of Health and Human Services, the Office of Management and Budget, the CIA, and the Department of Labor. Jennifer also worked for State Senator Bill Luther and for Fairbanks-Goodhue-Walaska counties in MN. Jennifer earned her law degree from Emory University in Atlanta, Georgia and is a member of the Bar in the State of Georgia. She earned her Bachelor’s degree from St. Olaf College in Northfield, Minnesota and studied in Brazil, Japan, Taiwan, China, Hong Kong and Thailand.

CAMILLE FABYI, PHD, MPH
Steering Committee Member - Federal Liaison

Dr. Fabiyi is the Senior Advisor for Women’s Health and Gender Research within the Office of Extramural Research, Education, and Regional Support (BERER) at the Agency for Healthcare Research and Quality (AHRQ). In this role, she conducts, supports, and oversees research on women’s health, perinatal health and health disparities in the context of healthcare system quality and improvement and patient safety. She also provides leadership and represents AHRQ on all matters related to women’s health and gender research issues. Prior to joining AHRQ, she served as a Senior Researcher at the University of Chicago in the Department of Obstetrics and Gynecology, where she conducted reproductive health research. Formerly, she served as the Project Director on federally-funded research projects in the areas of maternal and child health and aging at the University of Illinois at Chicago (UIC). Dr. Fabiyi received her PhD in Community Health Sciences with a concentration in Maternal and Child Health and her MPH in Health Policy and Administration at the UIC School of Public Health.

HOLLY FALK KRZESINSKI, PhD
Panelist - The Lifecycle of Communicating the Science panel

Holly J. Falk-Krzesinski, PhD, is the Vice President, Research Intelligence with the Global Strategic Networks team at Elsevier. Her key role is giving voice to research leaders at universities, funders, and science policy organizations to help Elsevier deliver the most impactful research information solutions to support research globally. Dr. Falk-Krzesinski serves as Co-chair of Elsevier’s Gender Equity Taskforce and is co-author on Elsevier’s two global gender analytics reports. Dr. Falk-Krzesinski is actively involved in the organization’s executive-level Inclusion & Diversity (I&D) efforts, advocating for greater gender diversity among STEMM leadership, and promoting sex and gender-based analyses reports. She serves as a member of the Elsevier Board of Directors and is an Elsevier Fellow. Her key role is giving voice to research leaders at universities, funders, and science policy organizations to help Elsevier deliver the most impactful research information solutions to support research globally. Dr. Falk-Krzesinski serves as Co-chair of Elsevier’s Gender Equity Taskforce and is co-author on Elsevier’s two global gender analytics reports. Dr. Falk-Krzesinski is actively involved in the organization’s executive-level Inclusion & Diversity (I&D) efforts, advocating for greater gender diversity among STEMM leadership, and promoting sex and gender-based analyses reports. She serves as a member of the Elsevier Board of Directors and is an Elsevier Fellow.

ANTHONY S. FAUCI, MD
Speaker – Evening Fireside Chat

Dr. Fauci was appointed Director of the National Institute of Allergy and Infectious Diseases (NIAID) in 1984. He oversees an extensive research portfolio of basic and applied research to prevent, diagnose, and treat established and emerging diseases such as Ebola and Zika. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies. The NIAID budget for fiscal year 2021 is an estimated $6.1 billion.

Dr. Fauci has advised seven Presidents on HIV/AIDS and many other domestic and global health issues. He was one of the principal architects of the President’s Emergency Plan for AIDS Relief (PEPFAR), a program that has saved millions of lives throughout the developing world.

CAMILLE FABIYI, PHD, MPH
Panelist – Creating Synergistic Partnerships: The Power of Working Together

Dr. Denny is the Chief Executive Officer of the National Institutes of Health’s All of Us Research Program. He has been involved in transdisciplinary research from its inception: first as a Member of the initial Scientific Advisory Board of the NIH Clinical Center’s Genomics Medicine Initiative Working Group, which developed the program’s initial scientific blueprint. He led the program’s initial prototyping project and served as the principal investigator for the All of Us Data and Research Center.

As a physician scientist, Josh is deeply committed to improving patient care through the advancement of precision medicine. Before joining the NIH, Josh was a Professor of Biomedical Informatics and Medicine, Director of the Center for Precision Medicine, and Vice President for Personalized Medicine at Vanderbilt University Medical Center. In his roles at VUMC, he was both a practicing internist and a researcher. His research interests include use of electronic health records (EHRs) and genomics to better understand disease and drug response. He also led efforts implementing precision medicine to improve patient outcomes. Josh was a leader in the development of phenotype-wide association studies (PheWAS) and phenotype risk scores. He served as PI for Vanderbilt sites in the Electronic Medical Records and Genomics (eMERGE) Network, Pharmacogenomics Research Network (PGRN), and the Implementing Genomics into Practice (iP2) Network.

He is an elected member of the National Academy of Medicine, the American Society for Clinical Investigation, and the American College of Medical Informatics.

JENNIFER DUCK, JD
Steering Committee Member

Jennifer Duck serves as Vice President of Public Affairs for Novo Nordisk Inc. Prior to joining Novo, Jennifer served as Staff Director and Chief Counsel of the Senate Judiciary Committee for the minority and as Chief of Staff for Senator Diane Feinstein of California. Jennifer spent several years working at Pfizer, Inc. as Vice President of Policy, External Affairs, and Communications.

Her previous government experience included serving as Staff Director and Chief Counsel on the Subcommittee of Terrorism, Technology and Homeland Security of the Senate Judiciary Committee, as well as counsel to Democratic Leader Tom Daschle, counsel for Senator Ted Kennedy on the Senate Health, Education, Labor and Pensions Committee; and, as a Senior Policy Advisor for the Senate Democratic Policy Committee.

Jennifer’s executive branch and state and local government experiences include time in the Clinton Administration at his Department of Labor’s Office of Intergovernmental Affairs where she managed outreach to state and local officials as well as with Congressional Affairs. Jennifer worked on the Obama Presidential Transition with the teams for the Department of Health and Human Services, the Office of Management and Budget, the CIA, and the Department of Labor. Jennifer also worked for State Senator Bill Luther and for Fairbanks-Goodhue-Walaska counties in MN. Jennifer earned her law degree from Emory University in Atlanta, Georgia and is a member of the Bar in the State of Georgia. She earned her Bachelor’s degree from St. Olaf College in Northfield, Minnesota and studied in Brazil, Japan, Taiwan, China, Hong Kong and Thailand.

CAMILLE FABIYI, PHD, MPH
Steering Committee Member - Federal Liaison

Dr. Fabiyi is the Senior Advisor for Women’s Health and Gender Research within the Office of Extramural Research, Education, and Regional Support (BERER) at the Agency for Healthcare Research and Quality (AHRQ). In this role, she conducts, supports, and oversees research on women’s health, perinatal health and health disparities in the context of healthcare system quality and improvement and patient safety. She also provides leadership and represents AHRQ on all matters related to women’s health and gender research issues. Prior to joining AHRQ, she served as a Senior Researcher at the University of Chicago in the Department of Obstetrics and Gynecology, where she conducted reproductive health research. Formerly, she served as the Project Director on federally-funded research projects in the areas of maternal and child health and aging at the University of Illinois at Chicago (UIC). Dr. Fabiyi received her PhD in Community Health Sciences with a concentration in Maternal and Child Health and her MPH in Health Policy and Administration at the UIC School of Public Health.

HOLLY FALK KRZESINSKI, PhD
Panelist - The Lifecycle of Communicating the Science panel

Holly J. Falk-Krzesinski, PhD, is the Vice President, Research Intelligence with the Global Strategic Networks team at Elsevier. Her key role is giving voice to research leaders at universities, funders, and science policy organizations to help Elsevier deliver the most impactful research information solutions to support research globally. Dr. Falk-Krzesinski serves as Co-chair of Elsevier’s Gender Equity Taskforce and is co-author on Elsevier’s two global gender analytics reports. Dr. Falk-Krzesinski is actively involved in the organization’s executive-level Inclusion & Diversity (I&D) efforts, advocating for greater gender diversity among STEMM leadership, and promoting sex and gender-based analyses reports. She serves as a member of the Elsevier Board of Directors and is an Elsevier Fellow. Her key role is giving voice to research leaders at universities, funders, and science policy organizations to help Elsevier deliver the most impactful research information solutions to support research globally. Dr. Falk-Krzesinski serves as Co-chair of Elsevier’s Gender Equity Taskforce and is co-author on Elsevier’s two global gender analytics reports. Dr. Falk-Krzesinski is actively involved in the organization’s executive-level Inclusion & Diversity (I&D) efforts, advocating for greater gender diversity among STEMM leadership, and promoting sex and gender-based analyses reports. She serves as a member of the Elsevier Board of Directors and is an Elsevier Fellow.

ANTHONY S. FAUCI, MD
Speaker – Evening Fireside Chat

Dr. Fauci was appointed Director of the National Institute of Allergy and Infectious Diseases (NIAID) in 1984. He oversees an extensive research portfolio of basic and applied research to prevent, diagnose, and treat established and emerging diseases such as Ebola and Zika. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies. The NIAID budget for fiscal year 2021 is an estimated $6.1 billion.

Dr. Fauci has advised seven Presidents on HIV/AIDS and many other domestic and global health issues. He was one of the principal architects of the President’s Emergency Plan for AIDS Relief (PEPFAR), a program that has saved millions of lives throughout the developing world.
Dr. Freire is the recipient of numerous awards, including the 2019 “Executive of the Year” Award from NonProfit PRO, the Access to Medicines. She is a member of the National Academy of Medicine and the Council on Foreign Relations. Sustainable Development Solutions Network; and was a member of the UN Secretary General’s High-Level Panel on Framework for the Future of the National Academy of Medicine and the Executive Committee of the United Nations’ Inc.; is on the Board of Directors for Exelixis, Inc.; has served as a member of the Commission on a Global Health Risk Foundation. From 2001 to 2008, she served as President and Chief Executive Officer of the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit organization that develops drugs to fight tuberculosis, and from 1995 to 2001, she served as the Office of Technology Transfer at the NIH.

Dr. Freire is active on national and international boards and committees. She is the Chair of the Business Advisory Board of the Institute for Research in Biomedicine in Barcelona, Spain, is a Director of Alexandria Real Estate Equities, Inc.; is on the Board of Directors for Exelixis, Inc.; has served as a member of the Commission on a Global Health Risk Framework for the Future of the National Academy of Medicine and the Executive Committee of the United Nations’ Sustainable Development Solutions Network; and was a member of the UN Secretary General’s High-Level Panel on Access to Medicines. She is a member of the National Academy of Medicine and the Council on Foreign Relations.

Dr. Freire is the recipient of numerous awards, including the 2019 “Executive of the Year” Award from NonProfit PRO, the 2017 Gold Stevie Award for “Woman of the Year”, the 2017 Washington Business Journal’s Who Mean Business Award, the HHS Secretary’s Award for Distinguished Service, the Arthur S. Fleming Award and the Bayh-Dole Award.

**CHANTEL FUQUA, PHD**

Steering Committee Member

Chantel F. Fuqua, Ph.D, is the Director of Faculty and Educational Initiatives at the Association of American Colleges (AACM). Currently, Dr. Fuqua manages the Minority Faculty Leadership Development Seminar, Mid-Career Faculty Leadership Development Seminar and Grant Writers’ Coaching Workshop for NIH Awards, along with conducting data analysis and other scholarship to promote faculty diversity. Previously, she served as a 2016–2018 American Association for the Advancement of Science (AAAS) Science and Technology Policy Fellow in the Division of Human Resources Development in the National Institute for Education and Human Resource Development, supporting the Louis Stokes Alliance for Minority Participation program. She also has experience providing scientific, evaluation, and technical support to the National Institutes of Health, along with the U.S. Army Medical Research and Materiel Command in the management of the congressionally Directed Medical Research Programs and other federal scientific programs. She has a strong interest in broadening participation in STEM disciplines and educational policy. Her prior research investigated the work-life balance policies for faculty at historical black colleges and universities through extensive scientific literature reviews, focus groups and workshops. This work supports the development of a matrix for future use by academic institutions to maximize faculty productivity and success. Dr. Fuqua has also taught biology, biochemistry, and chemistry at various types of higher education institutions.

**HILARY S. GAMMILL, MD**

Steering Committee Member; Subcommittee Member – “Putting Skin in the Game”:

The Economic Opportunity panel and Facilitator – Private Funders breakout session; Ce-chair – Societies’ Promise for Improved Science Culture: The Societal Opportunity panel

Hilary Gammill, MD is the Deputy Director for Maternal Health and Discovery on the Maternal, Newborn, and Child Health - Discovery & Tools team in the Global Health division at the Bill & Melinda Gates Foundation. Her specific areas of focus on the team include understanding drivers of adverse pregnancy outcomes, developing interventions to prevent and treat obstetric complications, and developing devices to optimize care and inform pregnancy risk stratification, all focused on low- and middle-income country contexts. A maternal-fetal medicine physician-scientist by training, Dr. Gammill joined the foundation in 2020. Prior to her current role, she worked at the University of Washington (UW) as an Associate Professor in Obstetrics and Gynecology.

Prior to attending medical school at UW in Seattle, Washington, Dr. Gammill completed her Obstetrics and Gynecology residency and Maternal-Fetal Medicine fellowship at Magee-Womens Hospital in Pittsburgh, Pennsylvania. She then returned to Seattle and joined the UW faculty, where she initially worked in the multidisciplinary research group of Dr. J. Lee Nelson, a leader in the field of microchimerism research, at the Fred Hutchinson Cancer Research Center and launched her own complementary research program at the UW. Dr. Gammill’s laboratory was part of the Center for Reproductive Sciences at UW’s dedicated research campus at South Lake Union. Her group focused on maternal-fetal exchange and immune interaction, and reproductive origins of maternal disease, with a particular emphasis on how material exchanged between mother and fetus during pregnancy can influence pregnancy outcomes and reflect placental status. In addition, her group investigated the durable persistence of cells exchanged between mother and fetus as microchimerism and their potential to influence later-life risk of and protection from diseases, for example in cardiovascular health before preclampsia.

**DANA GOLDMAN, PHD**

Steering Committee Member

Dana Goldman is the Interim Dean of the USC Sol Price School of Public Policy, where he holds the Leonard Schaeffer Chair and is a Distinguished Professor of Public Policy, Pharmacy, and Economics. Since its inception, Dr. Goldman has led the USC Schaeffer Center for Health Policy & Economics, one of the nation’s premier health policy programs. He is an elected member of the National Academy of Medicine and the National Academy of Social Insurance – two of his field’s highest honors. He is the author of more than 350 articles, and his research has been published in leading medical, economic, health policy, and statistics journals and other media. He has raised over $150 million in support of health policy research—including $50 million from the NIH. He has served as a health policy advisor to the Congressional Budget Office, Covered California, NIH, the Fred Hutchinson Cancer Institute, and several life sciences companies. He currently sits on the scientific advisory board at GRAL. Dr. Goldman is a member of the editorial boards of Health Affairs and the American Journal of Managed Care and was founding editor of the Forum for Health Economics and Policy. His work has been featured in the New York Times, Wall Street Journal, Washington Post, The Economist, NBC Nightly News and other media. He is a former director of ISPOR and ASHEcon. Dr. Goldman received his B.A. summa cum laude from Cornell University and a Ph.D. in Economics from Stanford University.
JENNIFER FRIEL GOLDESTON, BSE, MBA, MA
Steering Committee Member; Co-chair and Moderator – “Putting Skin in the Game: The Economic Opportunity panel

Jennifer Friel Goldston is the Managing Partner for Life Science & Healthcare at SVB Capital and a founding member of Venture Ecosystem, a non-profit that provides resources and education towards developing a diverse, equitable, and inclusive venture ecosystem. She is also an advisory board member of Springboard Enterprises and the Women’s Health Innovation Coalition. A bioengineer by training, Jennifer is passionate about the role that venture investing can bring to discovering in the fields of health care and life sciences. She is currently leading SVB Capital’s Life Science & Healthcare investment team targeting later-stage companies and managing some of the firm’s first life science direct investments currently in the pipeline. Prior to joining SVB Capital, Jennifer managed SVB’s $250 million private equity portfolio, which has included investments in several life sciences companies, led fund-of-fund investment decisions, and independently managed SVB’s $50 million private equity portfolio. Jennifer has also served as a consultant on private equity deals across Europe while at Bain & Company and has held operational and research roles at Chiron, Genentech, and Genencor.

Jennifer graduated magna cum laude with a BSE in Bioengineering and a Master of Biotechnology from the University of Pennsylvania. She holds an MBA from the Wharton School, where she was named a Joseph Wharton Fellow. She also serves as an independent director at Alexandria Real Estate Equities, Inc. Jennifer lives in the Bay Area with her husband and their twin children.

CARL V. HILL, PHD, MPH
Panelist – The Lifecycle of Communicating the Science panel

Carl V. Hill, Ph.D., MPH, is the chief diversity, equity and inclusion officer for the Alzheimer’s Association, overseeing strategic initiatives to strengthen the Association’s outreach to all populations, and providing communities with resources and support to address the Alzheimer’s crisis. In this role, Dr. Hill is responsible for developing cross-functional partnerships with organizations to advance diversity, equity and inclusion. As a result of his leadership, the Association has broadened its reach to previously diverse communities partners such as the African Methodist Episcopal Church and the Buddhist Tzu Chi Foundation.

Within the Association, Dr. Hill collaborates with human resources to attract talent and develop resources that champion staff diversity and a culture of inclusion. He authored an editorial in the journal of New England Medicine (JAMA) Neurology highlighting the need for more diverse perspectives to address disparities and pursue equity in dementia research.

Dr. Hill previously served as the Association’s vice president, Scientific Engagement. Prior to joining the Association, he served as director, Office of Special Populations at the National Institutes on Aging (NIA). Throughout Dr. Hill’s six years in this role, he led the development of the NIA Health Disparities and Health Equity Roadmap, a strategic framework aimed at addressing health disparities and inequities for individuals who belong to racial and ethnic minority groups.

Dr. Hill earned his Ph.D. from the University of Michigan School of Public Health, where he trained with the Center for Research on Racial and Cultural Health Disparities and the Program for Research on Black Americans (PRBA). He is an alumnus of the National Medical Fellowships Inc.; W.K. Kellogg Foundation Health Policy Fellowship Program. Dr. Hill holds a master’s degree in public health from Morehouse School of Medicine, and he received his Distinguished Alumni Award from the University of Illinois at Chicago in 2019. As a member of the Centers for Disease Control and Prevention’s (CDC) Public Health Prevention Service, a training and leadership program, he helped to establish the Center for Bioethics in Research and Healthcare at Tufts University.

The Association’s Alzheimer’s is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer’s and all other dementias — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer’s and all other dementias. For more information, visit alz.org.
Panelist – “Putting Skin in the Game”: The Economic Opportunity panel

Anula Jayasuriya is a successful private equity executive and venture capitalist whose background combines deep business, scientific, and medical knowledge with broad clinical, industry, entrepreneurial, and investment experience as a private and as an institutional investor. Integrating her passion with her investing expertise, in 2013 Anula founded EXXtreme Capital, an early-stage venture fund focused on catalyzing innovation, entrepreneurship and investment in Women's Health. In 2006 Anula co-founded Evolude India Life Science Fund, the first fund in India to focus exclusively on investing in India-based health care opportunities and the follow-on fund, India Life Science Fund II. Previously, Anula was a partner with Skyline Ventures in Palo Alto; a principal with TIV in San Francisco; VP Business Development at Genomics Collaborative Inc.; and Vice President, Global Drug Development at Hoffman-La Roche for opportunistic infections in AIDS and Transplantation. Anula received her BA from Harvard summa cum laude, and an MD and PhD in Microbiology and Molecular Genetics from Harvard Medical School. She interned in Pediatrics at Boston Children's Hospital and earned an MBA with distinction from Harvard Business School. Anula also holds an MPH in pharmacology from the University of Cambridge, in England.

Panelist – Government Agencies Call to Action panel

Michael Lauer, MD, is the Deputy Director for Extramural Research at the National Institutes of Health (NIH), where he serves as the principal scientific leader and advisor to the Director of the NIH on all matters relating to the substance, quality, and effectiveness of the NIH extramural research program and administration. He received education and training at Rensselaer Polytechnic Institute, Albany Medical College, Harvard Medical School, Harvard School of Public Health, and the NHLBI's Framingham Heart Study. He spent 14 years at Cleveland Clinic as Professor of Medicine, Epidemiology, and Biostatistics. During his tenure at the Clinic, he led a federally funded internationally renowned clinical epidemiology program that applied big data from large-scale electronic health platforms to questions regarding the diagnosis and management of cardiovascular disease. From 2015 to 2019, he served as a Division Director at the National Heart, Lung, and Blood Institute (NHLBI), where promoted efforts to leverage big data infrastructure to enable high-efficiency population and clinical research and efforts to adopt a research funding culture that reflected data-driven policy. He has received numerous awards including the NIH Equal Employment Opportunity Award of the Year and the Arthur S. Flemming Award for Exceptional Federal Service in recognition of his efforts to grow a culture of learning and accountability.

Panelist – Government Agencies Call to Action panel

Nathalie Le Bot, PhD, is the Senior Director of Nature Communications in 2019 and oversee the life and clinical sciences content published at the journal by a team of 60 editors. Nathalie was previously senior editor for stem cells and development at Nature Cell Biology for 8 years and Nature for 5 years. She is a member of Diversity, equity and inclusion working groups within the Nature portfolio. She has a keen interest for innovations and approaches aimed at increasing transparency in reporting in peer-reviewed articles. Nathalie joined Nature Communications in 2019 and oversee the life and clinical sciences content published at the journal by a team of 60 editors. Nathalie was previously senior editor for stem cells and development at Nature Cell Biology for 8 years and Nature for 5 years. She is a member of Diversity, equity and inclusion working groups within the Nature portfolio. She has a keen interest for innovations and approaches aimed at increasing transparency in reporting in peer-reviewed articles. Nathalie joined Nature Communications in 2019 and oversee the life and clinical sciences content published at the journal by a team of 60 editors. Nathalie was previously senior editor for stem cells and development at Nature Cell Biology for 8 years and Nature for 5 years. She is a member of Diversity, equity and inclusion working groups within the Nature portfolio. She has a keen interest for innovations and approaches aimed at increasing transparency in reporting in peer-reviewed articles.
Carolee Lee is an innovator, entrepreneur and thought leader dedicated to improving women’s health and wellbeing, and their opportunities to succeed. She was founded and CEO of Carolee Designs, one of the world’s leading accessory brands selling the company. Carolee focused her energies on women’s health and life planning. In 2008, she founded Access Circles, a global, by-invitation network committed to bringing women access to leaders, resources, and experiences that can help transform their lives.

In 2018, Carolee launched Women’s Health Access Matters (WHAM!), a nonprofit organization to improve the health and wellbeing of women by accelerating attention to sex and gender in medical research, to better understand health conditions that occur exclusively or predominately in women in order to develop solutions that optimize women’s health. Carolee has forged a research partnership with the RAND Corporation to highlight the economic costs, benefits and social impacts of investing in health research that focuses on women, and is using that data to erase the gender research gap and accelerate women’s health around the world.

Carolee is also a mentor and leader in business, philanthropic and educational organizations. She is a past Chair and Foundation Board Chair of the Committee of 200, a community of the most successful women in business, and has served as director on the board of DSW, Inc., a leading shoe retailer. Carolee is a founding board member of The Breast Cancer Research Foundation, where she has served since 1986. She currently sits on the Women’s Leadership Board at The John F. Kennedy School of Government at Harvard University.

RACHEL LEVINE, MD

Carolee Lee is an innovator, entrepreneur and thought leader dedicated to improving women’s health and wellbeing, and their opportunities to succeed. She was founded and CEO of Carolee Designs, one of the world’s leading accessory brands selling the company. Carolee focused her energies on women’s health and life planning. In 2008, she founded Access Circles, a global, by-invitation network committed to bringing women access to leaders, resources, and experiences that can help transform their lives.

In 2018, Carolee launched Women’s Health Access Matters (WHAM!), a nonprofit organization to improve the health and wellbeing of women by accelerating attention to sex and gender in medical research, to better understand health conditions that occur exclusively or predominately in women in order to develop solutions that optimize women’s health. Carolee has forged a research partnership with the RAND Corporation to highlight the economic costs, benefits and social impacts of investing in health research that focuses on women, and is using that data to erase the gender research gap and accelerate women’s health around the world.

Carolee is also a mentor and leader in business, philanthropic and educational organizations. She is a past Chair and Foundation Board Chair of the Committee of 200, a community of the most successful women in business, and has served as director on the board of DSW, Inc., a leading shoe retailer. Carolee is a founding board member of The Breast Cancer Research Foundation, where she has served since 1986. She currently sits on the Women’s Leadership Board at The John F. Kennedy School of Government at Harvard University.

Dr. Rachel Levine serves as the 17th Assistant Secretary for Health for the U.S. Department of Health and Human Services (HHS), after being nominated by President Joe Biden and confirmed by the U.S. Senate in 2021. As Assistant Secretary for Health, Dr. Rachel Levine fights every day to improve the health and well-being of all Americans. She’s working to help our nation overcome the COVID-19 pandemic and build a stronger foundation for a healthier future—one in which every American can attain their full health potential.

After graduating from Harvard College and Tulane University School of Medicine, Dr. Levine completed her training in Pediatrics and Adolescent Medicine at the Mt. Sinai Medical Center in New York City. As a physician, she focused on the intersection between mental and physical health, often treating children, adolescents, and young adults. Dr. Levine also served as Professor of Pediatrics and Psychiatry at the Penn State College of Medicine. Her previous roles included: Vice-Chair for Clinical Affairs for the Department of Pediatrics, and Chief of the Division of Adolescent Medicine and Eating Disorders at the Penn State Hershey Medical Center.

In 2015, Pennsylvania Governor Tom Wolf nominated Dr. Levine to be Pennsylvania’s physician general and she was subsequently unanimously confirmed by Pennsylvania’s state Senate. In 2017, Dr. Levine was named Acting Secretary of Health and confirmed to the position in March of 2018. During her time in state government, Dr. Levine worked to address Pennsylvania’s opioid crisis, focus attention on maternal health and improve immunization rates among children. Her decision to issue a standing order for the anti-overdose drug, Naloxone, saved thousands of lives by allowing law enforcement to carry the drug and Pennsylvanians to purchase it without a prescription from their doctor.

Dr. Levine is a fellow of the American Academy of Pediatrics, the Society for Adolescent Health and Medicine, and the Academy for Eating Disorders. She was also the President of the Association of State and Territorial Health Officials. In addition to her recent posts in medicine and government, Dr. Levine is an accomplished speaker and the author of numerous publications on the opioid crisis, adolescent medicine, eating disorders, and LGBT medicine.

Jennifer Luray is the Senior Advisor at Research!America, the nation’s largest nonprofit advocacy alliance for science, discovery, and innovation to achieve better health. She works across the organization to build partnerships with government agencies, programs with academia, patient advocates, and industry. Prior to joining Research!America, Ms. Luray directed U.S. policy and government affairs for Fortune 500 life-sciences companies, BD and Abbott. She partnered with internal and external stakeholders on public policy issues related to a range of drug, device and diagnostic technologies while advancing policy solutions to address medication safety, antibiotic stewardship and women’s health, among many other areas. Ms. Luray was Chief of Staff to former U.S. Senator Barbara Mikulski and Legislative Director to Congresswoman Nita Lowey. During the Clinton Administration, she was a Deputy Assistant to the President and Director of Women’s Initiatives and Outreach in the White House. Ms. Luray is a member of the Governing Committee of NESTcc, an FDA-funded initiative to research the use of real world data in medical device development. She is a member of the Advisory Board of the Brown University School of Public Health and the Stakeholder Advisory Board of the Johns Hopkins ALACRITY Center which supports mental health research. She currently chairs the Board of Directors of Planned Parenthood of Metropolitan Washington which serves 20,000 patients annually across the region. She received a B.A. in Sociology from Brown University and a Master in Public Administration from the Harvard Kennedy School of Government.

Mika Liss is Chief Operating Officer at the Neuroleadership Institute. Prior to NLI, Mika Liss worked in the Israeli high-tech industry at a publicly traded, global information technology and services firm. She joined that company when it was a start-up and grew with it from twenty-five people in one country into an international firm with six hundred employees in more than six countries.

Ms. Liss has held leadership roles in full Profit & Loss ownership, talent strategy and management, corporate communications, and sales operations. She’s lived in Tel Aviv, London, Paris, Atlanta, and New York City and led stock exchange listings, company re-brand initiatives, and mergers and acquisitions.

Common denouncers among her various positions are working as a partner to the CEO, founder, board members, investors, and other stakeholders. Her guiding principle: put sales and clients at the center of strategy.

Ms. Liss also teaches at New York University; her courses include Principles of Business Operation, Managing the Learning & Development Function, Designing Online Learning, and Transforming Organizations. She holds a Bachelor’s and Master’s in English Literature from New York University and Hunter College, respectively.

JENNY LURAY

Steering Committee Member; Co-chair and Moderator – Government Agencies Call to Action panel

Jennifer Luray is the Senior Advisor at Research!America, the nation’s largest nonprofit advocacy alliance for science, discovery, and innovation to achieve better health. She works across the organization to build partnerships with government agencies, programs with academia, patient advocates, and industry. Prior to joining Research!America, Ms. Luray directed U.S. policy and government affairs for Fortune 500 life-sciences companies, BD and Abbott. She partnered with internal and external stakeholders on public policy issues related to a range of drug, device and diagnostic technologies while advancing policy solutions to address medication safety, antibiotic stewardship and women’s health, among many other areas. Ms. Luray was Chief of Staff to former U.S. Senator Barbara Mikulski and Legislative Director to Congresswoman Nita Lowey. During the Clinton Administration, she was a Deputy Assistant to the President and Director of Women’s Initiatives and Outreach in the White House. Ms. Luray is a member of the Governing Committee of NESTcc, an FDA-funded initiative to research the use of real world data in medical device development. She is a member of the Advisory Board of the Brown University School of Public Health and the Stakeholder Advisory Board of the Johns Hopkins ALACRITY Center which supports mental health research. She currently chairs the Board of Directors of Planned Parenthood of Metropolitan Washington which serves 20,000 patients annually across the region. She received a B.A. in Sociology from Brown University and a Master in Public Administration from the Harvard Kennedy School of Government.

MIKA LISS

Steering Committee Member

Mika Liss is Chief Operating Officer at the Neuroleadership Institute. Prior to NLI, Mika Liss worked in the Israeli high-tech industry at a publicly traded, global information technology and services firm. She joined that company when it was a start-up and grew with it from twenty-five people in one country into an international firm with six hundred employees in more than six countries.

Ms. Liss has held leadership roles in full Profit & Loss ownership, talent strategy and management, corporate communications, and sales operations. She’s lived in Tel Aviv, London, Paris, Atlanta, and New York City and led stock exchange listings, company re-brand initiatives, and mergers and acquisitions.

Common denouncers among her various positions are working as a partner to the CEO, founder, board members, investors, and other stakeholders. Her guiding principle: put sales and clients at the center of strategy.

Ms. Liss also teaches at New York University; her courses include Principles of Business Operation, Managing the Learning & Development Function, Designing Online Learning, and Transforming Organizations. She holds a Bachelor’s and Master’s in English Literature from New York University and Hunter College, respectively.
Ms. Masterson has a long career in venture capital investments and Board of Directors work. She sits on early stage companies and public traded company boards. She coaches aspirational board candidates and is passionate about giving the DNA of the board right to support growth and success, financially for investors. As a lead investor in PPFAR where she invests $100k to $250k (in 3 funds) she supports women investors at that high level to create and develop new companies that women see to want from birth to menopause. She was a trial lawyer in women’s corporate sales management at Millipore and Amex Company and the first biotechnology analyst on Wall Street. As an entrepreneur she co-founded a DNA analysis company which was foundational to the genomics industry, called Sequenom. The company pioneered NPT testing and went public in 2000. As an Adjunct Professor at University of San Francisco she teaches the business of biotechnology as the co-chair of the San Francisco chapter of Women Corporate Directors. She has also been honored as an alumnus of achievement from Fordham University and is a published author and dynamic speaker. Her hobbies include horse-back riding and oil painting.

CELERI MAXWELL, MD, FACP, FIDSA

Dr. Maxwell is the Associate Dean for Research at Howard University College of Medicine. Dr. Maxwell is currently serving as the Principal Investigator of The Center for Infectious Disease Management and Research (CIDMR) Ryan White Part C and the Co-Principal Investigator for the HBCU Global Health Consortium (Zambia) and the Injury Medicine and Public Health Leadership Medicine at Howard University. She was formerly the Assistant Vice President for Health Sciences and Principal Investigator of several prestigious projects in the past, including: The Henry J. Kaiser Family Foundation Barbara Jordan Congressional Scholar Program at Howard University; The Program to Combat Violent Crimes Against Women on Campuses; the Mid-Atlantic AIDS Education and Training Center DC Local Performance Site at Howard University and the Center for Disease Control and Prevention-Comprehensive AIDS Training Initiative.

Dr. Maxwell was selected by Sharon Pratt-Kelly, former Mayor of Washington, D.C. to chair the Transito Task Force on AIDS and violence, and was also appointed to the Healthcare Reform Task Force chaired by First Lady, Hillary Rodman Clinton. Dr. Maxwell was appointed by Dr. Donna Shalala to the Secretary of Health and Human Services, and served as a Health and Human Services Research Advisory Council of the National Institutes of Health. Additionally, from 1994-97, she served as a Special Assistant to the Commissioner of Food and Drugs, Dr. David Kessler. Dr. Maxwell was selected for the prestigious Henry J. Kaiser Family Foundation Barbara Jordan Congressional Scholar Program at Howard University and the Center for Disease Control and Prevention-Comprehensive AIDS Training Initiative.

Dr. Maxwell was selected by Sharon Pratt-Kelly, former Mayor of Washington, D.C. to chair the Transito Task Force on AIDS and violence, and was also appointed to the Healthcare Reform Task Force chaired by First Lady, Hillary Rodman Clinton. Dr. Maxwell was appointed by Dr. Donna Shalala to the Secretary of Health and Human Services, and served as a Health and Human Services Research Advisory Council of the National Institutes of Health. Additionally, from 1994-97, she served as a Special Assistant to the Commissioner of Food and Drugs, Dr. David Kessler. Dr. Maxwell was selected for the prestigious Henry J. Kaiser Family Foundation Barbara Jordan Congressional Scholar Program at Howard University and the Center for Disease Control and Prevention-Comprehensive AIDS Training Initiative.

Dr. Maxwell was selected by Sharon Pratt-Kelly, former Mayor of Washington, D.C. to chair the Transito Task Force on AIDS and violence, and was also appointed to the Healthcare Reform Task Force chaired by First Lady, Hillary Rodman Clinton. Dr. Maxwell was appointed by Dr. Donna Shalala to the Secretary of Health and Human Services, and served as a Health and Human Services Research Advisory Council of the National Institutes of Health. Additionally, from 1994-97, she served as a Special Assistant to the Commissioner of Food and Drugs, Dr. David Kessler. Dr. Maxwell was selected for the prestigious Henry J. Kaiser Family Foundation Barbara Jordan Congressional Scholar Program at Howard University and the Center for Disease Control and Prevention-Comprehensive AIDS Training Initiative.

Dr. Maxwell was selected by Sharon Pratt-Kelly, former Mayor of Washington, D.C. to chair the Transito Task Force on AIDS and violence, and was also appointed to the Healthcare Reform Task Force chaired by First Lady, Hillary Rodman Clinton. Dr. Maxwell was appointed by Dr. Donna Shalala to the Secretary of Health and Human Services, and served as a Health and Human Services Research Advisory Council of the National Institutes of Health. Additionally, from 1994-97, she served as a Special Assistant to the Commissioner of Food and Drugs, Dr. David Kessler. Dr. Maxwell was selected for the prestigious Henry J. Kaiser Family Foundation Barbara Jordan Congressional Scholar Program at Howard University and the Center for Disease Control and Prevention-Comprehensive AIDS Training Initiative.

Michelle McMurry-Heath, MD, PhD

Dr. McMurry-Heath became just the third chief executive to steward the world’s largest biotechnology advocacy group since BIO’s founding in 1993. BIO represents 1,000 life sciences companies and organizations from 30 countries. The organization’s mission is to discover and deploy scientific breakthroughs that improve human health, environmental stewardship, and sustainable agriculture. The common thread in McMurry-Heath’s work across academia, government and industry has been her focus on broadening access to scientific progress so more patients can benefit from cutting-edge innovation. Driven by her own past family experiences navigating clinical trials and funding uncertainties within the rare disease community, her core belief is “the distribution of scientific progress the social justice issue of our age.” She continues her passion for scientific progress and social justice from Johnson & Johnson where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of the Johnson & Johnson Innovation & Global Leader for Regulatory Sciences. She was also an instrumental leader in the Johnson & Johnson incubator, JLabs, to Washington, DC. She led a global team of 900 with responsibilities in 150 countries around the globe. Prior to her time at J&J, Dr. McMurry-Heath was also a key science policy leader in government. The Obama-Biden transition team tapped her to serve as the Associate Science Director for the FDA’s Center for Devices and Radiological Health under Commissioner Dr. Margaret Hamburg, who was named by then President of the United States and the Alpha Omega Alpha Honor Medical Society. A native of Sandusky, Ohio, Leon and his wife, Natasha (Jones-McDougle, M.D.), are the proud parents of Peri and Autumn.

MICHELLE McMURR-Y-HEATH, MD, PhD

Steering Committee Member; Panelist – Moving Beyond Inclusion to Innovation: The Scientific Opportunity panel

Michelle McMurry-Heath, BIO President & CEO Michelle McMurry-Heath assumed the leadership of the Biotechnology Innovation Organization (BIO) as President and CEO on June 1, 2020. A medical doctor and molecular immunologist by training, Dr. McMurry-Heath became just the third chief executive to steward the world’s largest biotechnology advocacy group since BIO’s founding in 1993. BIO represents 1,000 life sciences companies and organizations from 30 countries. The organization’s mission is to discover and deploy scientific breakthroughs that improve human health, environmental stewardship, and sustainable agriculture. The common thread in McMurry-Heath’s work across academia, government and industry has been her focus on broadening access to scientific progress so more patients can benefit from cutting-edge innovation. Driven by her own past family experiences navigating clinical trials and funding uncertainties within the rare disease community, her core belief is “the distribution of scientific progress the social justice issue of our age.” She continues her passion for scientific progress and social justice from Johnson & Johnson where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of the Johnson & Johnson Innovation & Global Leader for Regulatory Sciences. She was also an instrumental leader in the Johnson & Johnson incubator, JLabs, to Washington, DC. She led a global team of 900 with responsibilities in 150 countries around the globe. Prior to her time at J&J, Dr. McMurry-Heath was also a key science policy leader in government. The Obama-Biden transition team tapped her to serve as the Associate Science Director for the FDA’s Center for Devices and Radiological Health under Commissioner Dr. Margaret Hamburg, who was named by then President of the United States and the Alpha Omega Alpha Honor Medical Society. A native of Sandusky, Ohio, Leon and his wife, Natasha (Jones-McDougle, M.D.), are the proud parents of Peri and Autumn.
**PHUONG KHANH MORROW, MD**
Steering Committee Member; Subcommittee Member: Moving Beyond Inclusion to Innovation: The Scientific Opportunity panel; Co-chair and Panelist – Creating Synergistic Partnerships: The Power of Working Together

Dr. P.K.'s primary role is as the Global Product General Manager for three early-stage oncology molecules focused upon MCL-1 and KRAS G12C. Furthermore, P.K. was appointed by the FDA to be the industry representative to the Oncology Drug Advisory Committee (ODAC) for a four-year term, ending in 2019.

In April 2019, P.K. became Vice President of Global Development and Therapeutic Area Head of Hematology, where she is responsible for guiding and accelerating late development activities addressing both marketed hematology programs (Blincyto and Kyprolis) and guiding the late development of programs that focus upon BCMA, FLT3, CD33, and MCL-1.

From 2014 to 2017, P.K. served as the Therapeutic Area Head for Oncology in the U.S. Medical Organization, where she oversaw U.S. oncology research activities, launch activities for newly approved oncology molecules, medical advocacy efforts, extramural research, and independent medical education grants. During this time, she successfully led the medical launch activities for IMLYGIC®, Kyprolis®, Neulasta Onpro™, and Blincyto®. In addition, P.K. served as the Global Product General Manager for three early-stage oncology molecules focused upon MCL-1 and KRAS G12C. Furthermore, P.K. was appointed by the FDA to be the industry representative to the Oncology Drug Advisory Committee (ODAC) for a four-year term, ending in 2019.

From 2013 through 2015, as the Neupogen® /Neulasta® Global Development Lead and US Medical Lead, P.K. led a cross-functional team in the development and registration of the Neulasta® Oncpro™, an investigational clinical and clinical trial in the successful submission of the Neupogen® and Neulasta® Acute Radiation Syndrome (ARS) sBLAs, leading to approval of both products for the ARS indication.

Prior to joining Amgen, P.K. was an Assistant Professor, Department of Breast Medical Oncology, at the University of Texas MD Anderson Cancer Center. She co-led the development of the first multidisciplinary breast cancer survivorship clinic at MD Anderson and served as the principal investigator of multiple drug studies.

**JESSICA MILES, PhD**
Steering Committee Member; Co-chair and Public Demand panel; Subcommittee Member – Steer gore Committee; Co-chair: Backed by Public Demand panel; Co-chair and Moderator – The Lifecycle of Communicating the Science panel

Jessica Miles, PhD, is a Senior Publisher at Cell Press. She manages 22 journals, including the Trends reviews and journals and several society titles, and leads a team of 16 PhD-Trained Editors to execute strategy across the portfolio and support innovation across Cell Press. She also co-chairs Elsevier’s forum for Sex and Gender-based Analysis in Research. Previously, Dr. Miles directed the high-profile Cell Symposia conference series and worked in the legal sector prior to joining Elsevier/Cell Press. She holds a doctorate in Microbiology from Yale University.

**ALONDRA NELSON, PHD**
Panelist – Government Agencies Call to Action panel

Dr. Alondra Nelson currently serves at the inaugural Deputy Director for Science and Society in the White House Office of Science and Technology Policy. In this role, she brings social science expertise, including attention to issues of social inequality, explicitly into the work of Federal science and technology strategy and policy. Dr. Nelson is also Harold F. Linder Chair and Professor at the Institute for Advanced Study, an independent research center in Princeton, N.J. She was president of the Social Science Research Council, an international research nonprofit from 2017-2021. She was previously professor of sociology at Columbia University, where she also served as the inaugural Dean of Social Science. Dr. Nelson began her academic career at the faculty of Yale University and there was recognized with the Poorvu Prize for interdisciplinary teaching excellence.

Dr. Nelson’s major research contributions are situated at the intersection of political and social citizenship, on the one hand, and emerging scientific, medical, and technological phenomena, on the other. Her work explores science, medicine, and technology as sites of both risk and empowerment, especially for underserved and vulnerable communities. Dr. Nelson connects these dimensions in a range of widely acclaimed and award-winning publications, including Technoscience: Race, Technology, and Everyday Life (with Thuy Linh N. Tu), Genetics and the Unsettled Past (with Keith Wailoo and Catherine Lee); Body and Soul: The Black Panther Party and the Fight Against Medical Discrimination; and The Social Life of DNA.

Dr. Nelson is a member of the American Academy of Arts and Sciences, the American Academy of Political and Social Science, the American Philosophical Society, and the National Academy of Medicine.
CHARLOTTE D. OWENS, MD, FACOG

Steering Committee Member; Co-chair and Panelist – Moving Beyond Inclusion to Innovation: The Scientific Opportunity panel

Charlotte D. Owens, MD, FACOG, is the Scientific Director in the Therapeutic Area Lead in U.S. Medical Affairs for Women's Health at AbbVie, and oversees the therapeutic area's scientific communications, educational efforts and publications. Prior to taking on her current role, Dr. Owens was responsible for helping lead the direction, planning, coordination, and execution of clinical trials to deliver high-quality clinical data at AbbVie, with a focus on women's health as a Medical Director in Clinical Development. In this role, she led clinical research to identify a new treatment option for symptomatic uterine fibroids in women: a fully enrolled and returned nearly 800 women, roughly two-thirds of whom were African-American women – a group that is typically underrepresented in research but disproportionally impacted by this disease. Immediately prior to joining AbbVie, Dr. Owens was an Assistant Clinical Professor of Obstetrics, Gynecology, and Reproductive Science at the David Geffen School of Medicine at UCLA. Dr. Owens received her B.S. in physiology from the University of California Davis, and her M.D. from the University of Michigan Medical School.

SUJIP PARIKH, PHD

Steering Committee Member; Panelist - Backed by Public Demand panel

Sujip Parikh, Ph.D., became the 19th chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals in January 2020. Parikh has spent two decades in the life sciences, serving in executive, managerial, and research capacities across academia and industry. Immediately prior to joining AAAS, Parikh was senior vice president and managing director at DIA Global, a neutral, multidisciplinary organization bringing together regulators, industry, academia, patients, and other stakeholders interested in the care patients receive and the care research and development programs that catalyze progress globally toward novel regulatory frameworks for advanced therapies not amenable to existing regulations. Previously, Parikh led Battelle's global AgriFood business unit. Headquartered in London and Geneva, this unit provided food safety and security advancements, healthcare devices, and creating advanced analytics and artificial intelligence applications to improve human health. Prior to DIA, Parikh led Battelle's global public and strategic healthcare consulting with expertise in business development and strategy, television news as a medical expert, and strategic healthcare consulting with expertise in multiple areas. In addition to her responsibilities at Battelle, she is a President-elect of the American Society for Clinical Pharmacology and Adjunct Clinical Professor at the Morehouse School of Medicine. Dr. Parikh received her B.S. in chemistry from the University of California, Davis, and her Ph.D. in chemistry from the University of Michigan, where she was a National Research Council Postdoctoral Research Associate in Professor David Eisenberg's lab.

GEMMA PHILIPPE, MPH

Steering Committee Member; Subcommittee Member: The Lifecycle of Communicating the Science panel; Co-chair - Backed by Public Demand panel; Facilitator - Professional Scientific/Medical Societies and Advocacy Organizations breakout session

Gemma Philips is a communication associate for the American Association for the Advancement of Science for Public Engagement with Science and Technology. She coordinates marketing and social media for Center programs, faciliates Communicating Science workshops, and supports other Center projects. Prior to joining AAAS in 2016, Gemma worked with both federal and private sector clients to promote occupational health and communication services and with volunteer organizations to promote adolescent health.

ELONA RIOS, MD, MSHP, FACP

Steering Committee Member; Facilitator - Academic Research Institutions breakout session

Dr. Rios serves as President & CEO of the National Hispanic Medical Association, (NHMA), representing 50,000 Hispanic physicians in the United States. The mission of the organization is to improve the health of Hispanics. Dr. Rios also serves as President of NHMA's National Hispanic Health Foundation to direct educational and research activities.

Dr. Rios also serves on the Board of Directors of the National Hispanic Leadership Agenda, a non-profit advocacy organization. The NHMA also serves as a Research Affiliate with the United States Hispanic Chamber of Commerce, National Hispanic Health Foundation, National Hispanic Medical Association, American Public Health Association Latino Caucus, Association of Hispanic Health Executives, Minority Health Month, Inc., Hispanic Magazine, Verizon's First Pollin Community Service Award, and Amerigroup. Dr. Rios was appointed to the Minority Alumni Hall of Fame of Stanford University in October, 2006, as a Fellow of the New York Academy of Medicine in 2007, the Institute of Medicine Global Forum for Health Professions Education in 2014, as a Fellow of the American College of Physicians in 2016, and as a member of the Society of Medical Administrators in 2017.

Prior to her current positions, Dr. Rios served as the Advisor for Regional and Minority Women's Health for the U.S. Department of Health and Human Services Office on Women's Health from November 1994 to October 1998. In 1998-2004, Dr. Rios was appointed to Executive Director, Hispanic Health Programs of the United States Department of Health and Human Services Office on Women's Health from November 1994 to October 1998. In 1998-2004, Dr. Rios was appointed to the National Health Care Reform Task Force as Coordinator of Outreach Groups for the White House. From 1992-94, Dr. Rios worked for the State of California Office of Statewide Health Planning and Development as a policy researcher.

Dr. Rios has also served as President, Chicano/Latino Medical Association of California, Founder of the National Network of Latin American Medical Schools, member of the California Department of Health Services Cultural Competency Steering Committee, and steering committee member of the OEPI Learning Community. Dr. Rios served as a member of the Board of Directors, Nurse Family Partnerships, Campaign Against Obesity, and Partnership for Prevention Boards of Directors, Physician Advisory Board, Hispanic Serving Health Professions Schools. In 1993, Dr. Rios was appointed to the National Health Care Reform Task Force as Coordinator of Outreach Groups for the White House. From 1992-94, Dr. Rios worked for the State of California Office of Statewide Health Planning and Development as a policy researcher.

Dr. Rios has also served as President, Chicano/Latino Medical Association of California, Founder of the National Network of Latin American Medical Schools, member of the California Department of Health Services Cultural Competency Steering Committee, and steering committee member of the OEPI Learning Community. Dr. Rios served as a member of the Board of Directors, Nurse Family Partnerships, Campaign Against Obesity, and Partnership for Prevention Boards of Directors, Physician Advisory Board, Hispanic Serving Health Professions Schools. In 1993, Dr. Rios was appointed to the National Health Care Reform Task Force as Coordinator of Outreach Groups for the White House. From 1992-94, Dr. Rios worked for the State of California Office of Statewide Health Planning and Development as a policy researcher.

Dr. Rios has also served as President, Chicano/Latino Medical Association of California, Founder of the National Network of Latin American Medical Schools, member of the California Department of Health Services Cultural Competency Steering Committee, and steering committee member of the OEPI Learning Community. Dr. Rios served as a member of the Board of Directors, Nurse Family Partnerships, Campaign Against Obesity, and Partnership for Prevention Boards of Directors, Physician Advisory Board, Hispanic Serving Health Professions Schools. In 1993, Dr. Rios was appointed to the National Health Care Reform Task Force as Coordinator of Outreach Groups for the White House. From 1992-94, Dr. Rios worked for the State of California Office of Statewide Health Planning and Development as a policy researcher.
LONDA SCHEIBINGER, PHD
Panelist - Teach 1 Reach 1: Academia’s Roll Call
Londa Scheibinger is the John L. Hinds Professor of History of Science at Stanford University, and Founding Director of Gendered Innovations in Science, Health & Medicine, Engineering, and Environment. Gendered Innovations harnesses the creative power of sex, gender, and intersexational analysis to enhance excellence and reproducibility in science. She is a leading international expert on gender in science and technology and has addressed the United Nations, the European Parliament, the Korean National Assembly, and numerous funding agencies on that topic. Scheibinger received her Ph.D. from Harvard University and is an elected member of the American Academy of Arts and Sciences. She is the recipient of numerous prizes and awards, including the prestigious Alexander von Humboldt Research Prize and Guggenheim Fellowship. From 2018-2020, she directed a European Commission expert group to produce: Gendered Innovations: How Gender Analysis Contributes to Research and Innovation (2018); Gendered Innovations in Science, Health & Medicine, Engineering, and Environment: How Gender Analysis Improves Science and Engineering (2019); and Sex and Gender Analysis: Improving Science and Gender Equity in Research (2020). Scheibinger is also the Executive Director of the Rosalind Franklin Society. With a prestigious board of men and women, including 5 Nobel Prize winners, the Rosalind Franklin Society is committed to empowering and supporting leaders in science and technology.

Her graduate work includes an M.Sc. from the London School of Economics and the Ph.D. program at Princeton University. She lives in Virginia with her husband, three children, and two dogs.

KATHRYN G. SCHUBERT, MPP
Kathryn G. Schubert (Katie) is President and CEO of the Society for Women's Health Research (SWHR), where she leads the organization’s efforts to promote research on sex as a biological variable and improve women’s health through science, policy, and education. Prior to joining SWHR in April of 2020, Katie served as Chief Advocacy Officer at the Society for Women’s Health Research (SWHR), where she oversaw health-related research, science policy, science communications, and communications activities. Prior to joining SWHR, she was a Senior Vice President at CRD Associates. Her clients included patient advocacy organizations, philanthropic organizations, scientific publishing organizations, and government and the Office of Science Policy and Communications, working with the FDA, HHS, and NHLBI on science related to women’s health. Her areas of expertise include with an emphasis on women’s health. She co-founded and chairs the National Science Policy Forum, a national science policy organization that provides science policy guidance to policy makers and advocates.

Her professional experience includes serving as CEO of the Women’s Brain Health Initiative, the first national organization dedicated to promoting research on sex, gender, and brain health. She served as the Executive Director of Women in Health and Public Policy, a national professional association for women in the government relations profession. She holds a Master of Public Policy degree with a concentration in health policy from The George Washington University and attended Mary Washington College in Fredericksburg, Virginia, where she earned a B.A. in Political Science. She lives in Virginia with her husband, three children, and dog, George.

JUDITH STEINBERG, MD, MPH
Steering Committee Member - Federal Liaison
Judith Steinberg is the Chief Medical Officer (CMO) of the Department of Health and Human Services Office of Infectious Disease and HIV/AIDS Policy (ODHP). This office, which is part of the Office of the Assistant Secretary for Health, coordinates the Ending the HIV Epidemic: A Plan for America initiative and the development and implementation of our nation’s strategic plans for HIV, viral hepatitis, sexually transmitted infections, vaccines and vector-borne diseases. As the CMO, Dr. Steinberg serves as a senior subject matter expert, providing medical and scientific expert advice and counsel across the broad infectious disease portfolio of the Office. Dr. Steinberg serves on the Advisor Committee for Immunization Practices COVID-19 vaccine safety technical subroup. She also served as the COVID-19 CMO for the US Public Health Service Commissioned Corps Command Center that oversees the COVID-19 deployments of our public health officers.

Prior to joining the ODHP, Dr. Steinberg was the CMO of the Bureau of Primary Health Care (BPHC), part of the Health Resources and Services Administration, which funds and administers the health center program. Dr. Steinberg was an associate professor of medicine at the University of Massachusetts (UMass) Medical School and an assistant professor of medicine at Boston University School of Medicine. She has more than 25 years of experience in primary care and infectious disease, including caring for patients at community health centers and safety net hospitals in Massachusetts. At UMass Medical School, she provided clinical expertise and leadership in the design and implementation of new healthcare delivery and value-based payment models.

Dr. Steinberg earned her medical degree from the University of Texas, and completed a residency in internal medicine at Beth Israel Hospital in Boston, as well as an infectious disease fellowship at Beth Israel/Brigham and Women’s Hospital in Boston. She was a Commonwealth Fund/Harvard University fellow in minority health policy and received a master’s degree in public health from Harvard University.
JANET STOVALL  
Panelist – Creating Synergistic Partnerships: The Power of Working Together

JANET STOVALL is a Senior Client Strategist at NeuroLeadership Institute (NLI). In her role at NLI, Janet helps organizations replace rigidity with agility to evolve with diversity, equity and inclusion practices to be more brain-friendly, more human—and more effective.

Janet's career evolved from a technical systems analyst role at Morgan Stanley into various corporate and agency management and public relations roles, including founding her own firm. Her most recent position was senior director for the CEO and senior leadership of UPS, one of the world's largest shipping and logistics companies, with more than 500,000 employees globally. She is one of the few Black-speechwriters to have worked at the C-level in the Fortune 500. Janet also led UPS's diversity, equity and inclusion communications, writing and producing an award-winning video, The Power of Difference, award-winning executive speeches, and serving as a founding member of the UPS Equity Task Force. She developed the team's vision and mission statements, and helped refine the company's framework for action to address racial inequity, and authored the company's first-year accomplishments report and recommendations. Janet also served as Senior Director, Social Impact and The UPS Foundation, working to advance UPS's global philanthropy, social impact and community engagement efforts. Her TEDx challenging business to get serious about inclusion has nearly 2 million views.

Janet holds a bachelor's degree in English from Davidson College, a master's degree in Integrated Marketing Communications from Georgetown University, and post-graduate certificates in Diversity and Inclusion from Cornell University and Yale University.

KIM TEMPLTON, MD, FAADS, FASA  
Panelist – Teach 1 Reach 1: Academia's Roll Call

Kim Templeton, MD, is Professor of orthopaedic surgery at the University of Kansas Medical Center in Kansas City and department vice-chair for diversity and equity. She was the first McCann Professor of Women in Medicine and Science in the United States. She received the inaugural Women Leaders in Medicine Award from the American Medical Student Association in 2018, the Marjorie S. Siddidge leadership award for women in medicine from the University of Kansas in 2012, the AMWA Elizabeth Blackwell Award for outstanding contributions to the cause of women in the field of medicine in 2013, and the AMWA Bertha Van Hoesen Award in 2019 for exception leadership and service to women physicians and students. She was named to the University of Kansas Women's Hall of Fame and is an honorary alumna of the University of Kansas in 2014.

Dr. Templeton is a past-president of the American Medical Women's Association. During her tenure as president of AMWA, Dr. Templeton developed the organization's Wellness Initiative and continues to lead that. Dr. Templeton is also co-chair of the AMWA Opioid Addiction task force. Dr. Templeton is past-president and a current member of the Kansas State Board of Healing Arts. During her tenure as president of the KSBHA, she helped develop a new category of "re-entry license", one of the few such in the US. In 2019, Dr. Templeton graduated with a B.A. in Biology from Whitman College. She holds a Ph.D. in Microbiology and Immunology from the University of Rochester School of Medicine and Dentistry, where she received numerous awards including the " Trollie" Research Award for Distinction. She completed post-doctoral training with CDMPR administrative support. Dr. Templeton is past vice-chair of the AMA Women's Student Association in 2008, the Marjorie J. Siddridge leadership award for women in medicine from the University of Rochester, a member of committees within the NQF and the bone and joint expert review committee of the NCQA. Dr. Templeton is a member of the USBJI, she helped develop the "expanded definition of 'women's health". Dr. Templeton is a member of the NBME Physician Section and past chair of the AMA Orthopaedic Section. She initiated and worked with the AMA in developing their new policy that recognizes an "expanded definition of women's health". Dr. Templeton is also co-chair of the AMWA Opioid Addiction in Women Task Force. Dr. Templeton is a past president of the US Bone and Joint Initiative. During her tenure as president of the USBJI, she developed and manages public education programs to address the burden of musculoskeletal disabilities. Dr. Templeton is past-president and a current member of the Kansas State Board of Healing Arts. During her tenure as president of the KSBAHA, she helped develop a new category of "re-entry license", one of the few such in the US. In 2019, Dr. Templeton worked with the Board to change licensure language to no longer ask about specific application of health issues to encourage those in healthcare to seek the care that they need. Dr. Templeton is a member of the Kansas prescription drug monitoring program advisory committee and the HealthyWomen chronic pain task force.

Dr. Templeton's publications focus on issues faced by women physicians and the inclusion of sex and gender concepts in medicine and health professionals' education. Her work addresses issues of women physicians extends from medical students to those nearing the end of practice and includes such topics as burnout and re-entry to practice. Dr. Templeton was the lead author on the National Academy of Medicine paper on burnout among women physicians that came out in 2019 and the senior author of a paper published in 2020 that was the first to address issues faced by senior women physicians.

GAYLE VADAY, PHD  
Steering Committee Member - Federal Liaison; Facilitator - Federal Partners breakout session; Speaker – Readout Reports for the Breakout Sessions

Dr. Gayle Vaday is currently the Director of the Congressionally Directed Medical Research Programs (CDMRP). She also serves as a Deputy Director for Program Management, and previously served as the Program Manager of Breast Cancer Research Program at CDMRP for 14 years. Dr. Vaday provides senior leadership support for medical research with a portfolio totaling over $1.5 billion per year; through strategic planning, process development and improvement, and coordination with DoD and external stakeholders. She leads scientific staff to execute the acquisition programs and provides technical support to CDMRP administrative areas.

Dr. Vaday graduated with a B.A. in Biology from Whitman College. She holds a Ph.D. in Microbiology and Immunology from the University of Rochester School of Medicine and Dentistry, where she received numerous awards including the " Trollie" Research Award for Distinction. She completed post-doctoral training with CDMPR administrative support at the Weizmann Institute of Science. Prior to joining the CDMRP in January 2006, Dr. Vaday was a Research Assistant Professor at Stony Brook University and a Research Scientist at the Northport Veterans Affairs Medical Center. Her research was funded by the Department of Veterans Affairs, Carol M. Baldwin Breast Cancer Research Fund, and Walk for Beauty.

Dr. Vaday has represented CDMRP at diverse forums including national conferences, advocacy groups, the National Academy of Medicine, and Congressional and VIP visits. She serves as a member of the Interagency Breast Cancer and Environmental Research Coordinating Committee, Advisory Committee for Breast Cancer in Young Women, and Metastatic Cancer Research Task Force. She served on the working group that developed CDMRP's policy on inclusion of Women and Minorities in Clinical Research. Dr. Vaday is a member of the Interagency Breast Cancer and Environmental Research Coordinating Committee, Advisory Committee for Breast Cancer in Young Women, and Metastatic Cancer Research Task Force. She served on the working group that developed CDMRP's policy on inclusion of Women and Minorities in Clinical Research. Dr. Vaday is a member of the Interagency Breast Cancer and Environmental Research Coordinating Committee, Advisory Committee for Breast Cancer in Young Women, and Metastatic Cancer Research Task Force. She served on the working group that developed CDMRP's policy on inclusion of Women and Minorities in Clinical Research. Dr. Vaday is a member of the Interagency Breast Cancer and Environmental Research Coordinating Committee, Advisory Committee for Breast Cancer in Young Women, and Metastatic Cancer Research Task Force. She served on the working group that developed CDMRP's policy on inclusion of Women and Minorities in Clinical Research. Dr. Vaday is a member of the Interagency Breast Cancer and Environmental Research Coordinating Committee, Advisory Committee for Breast Cancer in Young Women, and Metastatic Cancer Research Task Force. She served on the working group that developed CDMRP's policy on inclusion of Women and Minorities in Clinical Research.

JAN VAN DIS, MD  
Steering Committee Member; Co-chair and Panelist – Societies’ Promise for Improved Science Culture: The Societal Opportunity panel

Dr. Jane Van Dis is an OBGYN with OB Hospitalist Group, and soon to be Assistant Faculty in the Department of Obstetrics at the University of Rochester. She is currently Medical Director at Maven Clinic, Co-Founder of Equity Quotient and Equity Metric, equity solutions for healthcare. Dr. Van Dis is also Co-Founder of ObBest Practice which advises OBG Project, an online resource for ObGyns and learners. She is a Co-Founder of TIMESUP Healthcare. She advises OBG Project, an online resource for ObGyns and learners. She is a Co-Founder of TIMESUP Healthcare. She lectures frequently on gender and equity in healthcare and has published on the topic in the New England Journal of Medicine and Harvard Business Review. In addition, Dr. van Dis advises multiple health care startups and is a Lead Investor at Portfolio. She is a single mom to twins, Brooklyn and Miles.

GAYLE VADAY, PHD  
Steering Committee Member - Federal Liaison; Facilitator - Federal Partners breakout session; Speaker – Readout Reports for the Breakout Sessions

Dr. Gayle Vaday is currently the Director of the Congressionally Directed Medical Research Programs (CDMRP). She also serves as a Deputy Director for Program Management, and previously served as the Program Manager of Breast Cancer Research Program at CDMRP for 14 years. Dr. Vaday provides senior leadership support for medical research with a portfolio totaling over $1.5 billion per year; through strategic planning, process development and improvement, and coordination with DoD and external stakeholders. She leads scientific staff to execute the acquisition programs and provides technical support to CDMRP administrative areas.

Dr. Vaday graduated with a B.A. in Biology from Whitman College. She holds a Ph.D. in Microbiology and Immunology from the University of Rochester School of Medicine and Dentistry, where she received numerous awards including the " Trollie" Research Award for Distinction. She completed post-doctoral training with CDMPR administrative support.

Dr. Vaday is a member of the Kansas prescription drug monitoring program advisory committee and the HealthyWomen chronic pain task force.

Dr. Templeton was the lead author on the National Academy of Medicine paper on burnout among women physicians that came out in 2019 and the senior author of a paper published in 2020 that was the first to address issues faced by senior women physicians. She is a member of committees within the NQF and the bone and joint expert review committee of the NCQA. Dr. Templeton is a member of the USBJI, she helped develop the "expanded definition of 'women's health". Dr. Templeton is a member of the NBME Physician Section and past chair of the AMA Orthopaedic Section. She initiated and worked with the AMA in developing their new policy that recognizes an "expanded definition of women's health". Dr. Templeton is a member of the NIH Research Task Force. Dr. Templeton is a past president of the US Bone and Joint Initiative. During her tenure as president of the USBJI, she developed and manages public education programs to address the burden of musculoskeletal disabilities. Dr. Templeton is a past president and a current member of the Kansas State Board of Healing Arts. During her tenure as president of the KSBAHA, she helped develop a new category of "re-entry license", one of the few such in the US. In 2019, Dr. Templeton worked with the Board to change licensure language to no longer ask about specific application of health issues to encourage those in healthcare to seek the care that they need. Dr. Templeton is a member of the Kansas prescription drug monitoring program advisory committee and the HealthyWomen chronic pain task force.

Dr. Templeton's publications focus on issues faced by women physicians and the inclusion of sex and gender concepts in medicine and health professionals’ education. Her work addresses issues of women physicians extends from medical students to those nearing the end of practice and includes such topics as burnout and re-entry to practice. Dr. Templeton was the lead author on the National Academy of Medicine paper on burnout among women physicians that came out in 2019 and the senior author of a paper published in 2020 that was the first to address issues faced by senior women physicians.
KAVETA P. VASISHT, MD, PHARM
Steering Committee Member - Federal Liaison; Panelist – Moving Beyond Inclusion to Innovation: The Scientific Opportunity panel

Dr. Kaveta Vasisht is Associate Commissioner for Women's Health and serves as the Director of the Office of Women's Health (OWH) in the Office of the Commissioner of the US Food and Drug Administration (FDA). In this capacity, she serves as a member of HHS’s Senior Leadership Council. As associate commissioner and other top agency officials on essential issues related to women's health. In addition to promoting the inclusion of women in clinical trials through scientific policies, program development, research, education, outreach, and collaboration across agencies and sex and gender differences to facilitate FDA regulatory decision making. In addition to directing OWH, Dr. Vasisht represents FDA on various cross-agency expert committees and leads and/or contributes to the health of women, including the Task Force on Research Special Emphasis on Lactating Women (PRGLAC). Prior to joining the Office of Women's Health, Dr. Vasisht served as the Deputy Director for Public Affairs at the Food and Drug Administration in the Office of the Commissioner. Dr. Vasisht began her career at the FDA in the Division of Metabolism and Endocrine Products, Office of New Drugs, where she served as research staff in the Endocrinology Branch. Dr. Vasisht is passionate about seeing women’s voices in science and policy decisions regarding risk-benefit assessments on the safety and effectiveness of therapeutics for the U.S. population.

Dr. Vasisht is board-certified in both internal medicine and endocrinology and metabolism and holds a Doctor of Pharmacy degree. She completed her fellowship training in internal medicine and fellowship training at the University of Chicago Hospitals, where she also served on the faculty. She obtained her medical degree from the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School.

JANICE L. WERBSKI, MD
Steering Committee Member; Co-chair – Teach 1 Reach 1: Academia's Roll Call; Facilitator – Academic and Research Institutions breakout session; Speaker – Readout Reports for the Breakout Sessions

Dr. Janice Werbski is a Senior Medical Director for US Medical Affairs in the Bayer Women's HealthCare division. She is a board-certified OB/GYN and holds a Bachelor of Science in Biological Sciences from Northwestern University and a Master of Science in Clinical Investigation from Washington University School of Medicine. She has more than 30 years of experience in the areas of Women's Health, Reproductive Health and Men's Health. Dr. Werbski is passionate about sex and gender-appropriate medicine, with the goal of improving the health and healthcare of women. As the Scientific Opportunity panel member, she is dedicated to women’s health. In addition to promoting the inclusion of women in clinical trials and the completion of sex/gender studies, she is dedicated to ensuring that women and men are included in clinical trials and that sexual and gender differences are considered in clinical trials.

Dr. Werbski received her Bachelor of Science degree in Biological Sciences from Northwestern University and a Master of Science degree in Clinical Investigation from Washington University School of Medicine. She completed her OB/GYN residency at Vanderbilt University Medical Center in Nashville, Tennessee, and her fellowship in Reproductive Endocrinology at Yale University. She has published numerous research articles in peer-reviewed scientific journals and has presented at numerous national and international conferences. Dr. Werbski is a member of the American College of Obstetricians and Gynecologists and the Society for Women's Health Research. She is also a member of the Society for Academic Ob/Gyn and the Society for Women's Health Research. She has received numerous awards for her work including the Excellence in Women's Health Award from the Society for Women's Health Research and the Women's Health Research Foundation. Dr. Werbski is also a member of the American College of Obstetricians and Gynecologists and the Society for Women's Health Research. She has received numerous awards for her work including the Excellence in Women's Health Award from the Society for Women's Health Research.

JAMIE WHITE, MS
Steering Committee Chair

Jamie White is the Steering Committee Chair of the 5th Annual Vivian Pinn Symposium. She serves as the Health Science Strategy and Relations Lead in the Office of Research on Women's Health (ORWH). In this position, she provides strategic guidance and collaborates with ORWH and NIDDK to develop policy and programmatic challenges in science, health, and the biomedical workforce that are of significant relevance to the agency. Additionally, she conducts a wide range of staff functions involving strategic and policy planning, cross-divisional project management, and maintaining and creating internal and external partnerships through strategic engagement.

Jamie began her career at NIH as a Presidential Management Fellow (PMF) – STEM acting as the Special Assistant to the Director of ORWH. Prior to her PMF-STEM fellowship, she worked as a Laboratory Analyst for the Blue Grass Chemical Agent Destruction Pilot Plant (BFICAP) and Math and Science Tutor for the Professional Tutors of America and Variety Tutors. Early in her career, she was a Research Chemist at the Center for Disease Control and Prevention (CDC) and a Leadership Fellow in the Office of the Medical Policy in the Center for Drug Evaluation and Research (CDER). Dr. White attended Mount Holyoke College, where she majored in biology, and attained an apprenticeship under an obstetrician for a few years. Under this apprenticeship and while being in the program, she was granted exposure to and able to interface with the healthcare system outside of just being a patient. She had the opportunity to witness over 100 births and several gynecological procedures and cases. Jamie credits much of her interest for science, medicine, research, and health equity to programs such as the Women's Health Equity Act, as well as opportunities she was privileged to participate in during some formative summers, such as the Mathematics & Science for Minority Students (MS-2) – Academy Andover Outreach program and the Summer Multicultural Advancement Research Training (SMART) program at University of North Texas, among others. In her role at ORWH, Jamie is grateful to work towards the advancement of women in biomedical careers and research on the health of women, carrying on the mission and legacy of the Office. She has been involved with many policy initiatives and legislative proposals which would advance diversity and inclusion in biomedical careers and research. She has been involved with many policy initiatives and legislative proposals which would advance diversity and inclusion in biomedical careers and research.

Susan F. Wood is Research Professor of Health Policy and Management at the George Washington University Milken Institute School of Public Health. She also is the Director of the Jacobs Institute of Women’s Health, which publishes the peer reviewed journal, Women’s Health Issues. Prof Wood’s work focuses on women’s health and health equity, with a particular focus on health equity and social determinants of health, including risk-benefit assessments on the safety and effectiveness of therapeutics for the U.S. population.

Dr. Wood received her M.S. in Health Administration from the George Washington University School of Public Health and her B.S. in Biology from the University of Maryland. Prior to joining NIH as a Presidential Management Fellow (PMF)–STEM acting as the Special Assistant to the Director of ORWH, she worked on Capitol Hill as professional staff for the Congressional Caucus for Women’s Issues and as the Policy and Program Development at the U.S. Preventive Services Task Force. In her role at NIH, Dr. Wood began her career with the Office of Women’s Health and the Office of Research on Women’s Health (ORWH). She served as the clinical expert on multidisciplinary teams in the diverse field of women’s health research.

Dr. Wood has been a strong advocate for women’s health at the NIH, serving as ORWH’s signature event and a critical national event for women’s health research.

Susan F. Wood is Research Professor of Health Policy and Management at the George Washington University Milken Institute School of Public Health. She is also the Director of the Jacobs Institute of Women’s Health, which publishes the peer reviewed journal, Women’s Health Issues. Prof Wood’s work focuses on women’s health and health equity, with a particular focus on health equity and social determinants of health, including risk-benefit assessments on the safety and effectiveness of therapeutics for the U.S. population.

Dr. Wood began her career with the Office of Women’s Health and the Office of Research on Women’s Health (ORWH). She served as the clinical expert on multidisciplinary teams in the diverse field of women’s health research.

Dr. Wood has been a strong advocate for women’s health at the NIH, serving as ORWH’s signature event and a critical national event for women’s health research.

Dr. Wood has been a strong advocate for women’s health at the NIH, serving as ORWH’s signature event and a critical national event for women’s health research.

Dr. Wood has been a strong advocate for women’s health at the NIH, serving as ORWH’s signature event and a critical national event for women’s health research.
ELIZABETH YANO, PHD, MSPH
Steering Committee Member - Federal Liaison; Panelist – Government Agencies Call to Action panel

Dr. Yano is Director of the VA HSR&D Center for the Study of Healthcare Innovation, Implementation, & Policy at the VA Greater Los Angeles Healthcare System and Adjunct Professor of Health Policy & Management at the UCLA Geffen School of Public Health and of Medicine at the UCLA Geffen School of Medicine. With over 30 years of experience, Dr. Yano’s primary research expertise is in evaluating impacts of primary care and women’s health care delivery models and testing evidence-based quality improvement approaches for implementing and/or tailoring care models to improve quality, patient experience, and health outcomes. She has had a central role in building VA’s women’s health research capacity, leading development of VA’s women’s health research agenda and directing the VA Women’s Health Research Network (WHRN) (2010-present), for which she leads a national Consortium of researchers to accelerate research development. Dr. Yano also co-leads the VA Women’s Health Practice Based Research Network, comprised of 73 VA medical centers and over 300 community-based outpatient clinics to foster inclusion of women veterans in VA research. She has advanced multi-level stakeholder engagement methods to foster implementation and spread of research evidence through collaborative networks on the frontlines of care while her research has had measurable impacts on evidence-based practice and policy. WHRN has since served as a model for building widespread collaborative capable of accelerating research impacts on Veterans’ care in areas of chronic pain/osteo, access, virtual care, and suicide prevention. She also leads the Implementation & Training Core of the Coordinating Hub to Promote Research Optimizing Veteran-Centric Electronic Health Record (EHR) Networks (PROVEN), which seeks to accelerate EHR-related research with VA’s implementation of a new $16 billion EHR. She also leads a secondary analysis study capitalizing on inclusion of Veteran and VA-user status in National Health Interview Survey and other data enabling comparisons and contrasts in disease burden and utilization among Veteran-VA users, non-users and civilians, with a focus on health equity. Dr. Yano co-directs the VA Advanced Fellowship in Women’s Health and serves as faculty mentor for an array of early and mid-career researchers focused on women’s health, primary care, and partnered research driving Learning HealthCare Systems toward improved performance. She is on the Board of Directors for AcademyHealth, the nation’s premier health services research and health policy professional organization, dedicated to moving evidence into action, and has provided expert scientific review for NIH, AHRQ, PCORI, and VA and delivered numerous Congressional briefings and testimony on women Veterans’ health research. She has received the VA HSR&D Senior Research Career Scientist Award, the VA Under Secretary for Health Award for Outstanding Achievement in Health Services Research, the Breslow Lifetime Achievement Award for Health Services Research. She has received the VA HSR&D Senior Research Career Scientist Award, the VA Under Secretary for Health Award for Outstanding Achievement in Health Services Research, the Breslow Lifetime Achievement Award for Health Services Research.

JULIE M. ZISSIMOPOULOS, PHD
Panelist - Moving Beyond Inclusion to Innovation: The Scientific Opportunity panel

Julie M. Zissimopoulos is Associate Professor in the Sol Price School of Public Policy at the University of Southern California. In addition to her faculty appointment, she serves as Director of Aging and Cognition Research Program and Research Training at the Schaeffer Center for Health Policy and Economics. She is Director of USC’s Resource Center for Minority Aging Research, and Center for Advancing Sociodemographic and Economic Study of Alzheimer’s Disease and Related Dementias (CeASES-ADRD), both focused on reducing burden of Alzheimer’s disease and funded by the National Institute on Aging (NIA). Dr. Zissimopoulos is currently leading several NIA-funded research projects on: the health of caregivers for persons with dementia; the use of and response to drug therapies for non-Alzheimer’s disease and related dementia conditions that influence risk of dementia; racial and ethnic disparities in diagnosis and health care treatment for dementia; and measuring incidence and prevalence of dementia using Medicare claims and survey data. Her recently published research appears in numerous publications such as the Journal of the American Medical Association Neurology, Journal of Gerontology Social Science, Journal of the American Academy of Arts and Sciences, Journal of Health Economics and Alzheimer’s and Dementia. Her research on the economics of aging is disseminated through media outlets such as the New York Times, Washington Post, Los Angeles Times, CNN, National Public Radio. Dr. Zissimopoulos received her B.A. summa cum laude from Boston College, her M.A. from Columbia University, and a Ph.D. in economics from the University of California, Los Angeles.
The NIH Office of Research on Women's Health (ORWH) serves as the focal point for women's health research at NIH. ORWH was established in September 1990 in response to congressional, scientific, and advocacy concerns that a lack of systemic and consistent inclusion of women in NIH-supported clinical research could result in clinical decisions being made about health care for women based solely on findings from studies of men—without any evidence that they were applicable to women. ORWH is the first Public Health Service office dedicated specifically to promoting women's health research within, as well as beyond, the NIH scientific community. The office also fosters the recruitment, retention, reentry, and advancement of women in biomedical careers. Through its work and position as a trans-NIH office, and in partnership with the NIH institutes, Centers, and Offices (ICOs), ORWH has been able to:

TRANSFORM the term "women's health," including "women's health research," from a small and narrow conceptualization focused only on reproductive health to a broader and more expansive definition. Today, "women's health" is considered everything that affects a woman from head to toe, including internal and external factors, across the life course, which is a view referred to as the multidimensional framework.

ACCELERATE research that supports the expanded view of women's health, by funding innovative mechanisms such as the Specialized Centers of Research Excellence (SCORE) on Sex Differences program and the Building Interdisciplinary Research Careers in Women's Health (BIRCWH, pronounced "birch") program.

ENHANCE biomedical research by issuing supplemental funding to account for sex and gender influences in established and new research studies.

CREATE resources to help scientists more efficiently and effectively recruit and retain women participants in clinical studies. Now, over half of participants in NIH clinical trials are women, and we can examine inclusion data by disease categories.

ISSUE A CALL TO ACTION on maternal morbidity and mortality (MMM) through enhanced research, which is a critical determinant of the health of women and future generations. ORWH is galvanizing Federal and non-Federal stakeholders to review current data and programming related to MMM and has also developed the NIH Maternal Morbidity and Mortality Web Portal as a valuable resource.

ESTABLISH the U3 Program, the only NIH program focused on understudied, underrepresented, and underreported populations of women facing substantial health disparities.

SPEARHEAD the development and implementation of the NIH Policy on Sex as a Biological Variable (SABV), and effectively tether SABV to a national and international movement to remove bias against female biology at the preclinical research stage — a huge contribution to science that benefits women, men, girls, and boys.

SUPPORT women in biomedical careers by providing mentoring opportunities (such as through ORWH’s BIRCWH program) and by discovering and sharing evidence about effective best practices to promote the advancement of women in science at all stages of their career.

DEVELOP online and interprofessional educational resources to promote the recognition of sex differences during research and clinical training at all levels and across multiple disciplines.

CATALYZE many scientific advances, such as the HPV vaccine, which has the power to prevent cervical cancer, and a novel treatment for urinary tract infections that does not rely on antibiotics, thereby helping to address the worldwide crisis of antimicrobial resistance.

Since its establishment in 1990, the work, reach, and impact of ORWH has significantly expanded, not only in the increase of programs but also in the scope of its influence. Although we might never be able to quantify individual shifts in thinking or pinpoint all of the scientific advances that have resulted from ORWH's efforts, we can rest assured that science and the health of women greatly benefit from the ongoing dedication of ORWH and its partners.
About the
Foundation for the National Institutes of Health (FNIH)

The Foundation for the National Institutes of Health creates and leads alliances and public-private partnerships that advance breakthrough biomedical discoveries and improve the quality of people’s lives.

The Foundation, also known as the FNIH, works with its partners to accelerate biomedical research and strategies to fight against diseases in the United States and across the world. The FNIH organizes and administers research programs; supports education and training of new researchers; organizes educational events and symposia; and administers a series of funds supporting a wide range of health challenges.

The FNIH was established by Congress in 1990 as a not-for-profit 501(c)(3) charitable organization. The Foundation began its work in 1996 to support the mission and facilitate groundbreaking research at the NIH and worldwide. Convening otherwise diverse or competitive research efforts around a common mission, the FNIH brings dynamism, energy and urgency to finding treatments and cures for patients.

Visit our new website at fnih.org.

The Foundation for the National Institutes of Health extends its gratitude to the following sponsors for their support of this symposium.
5th Annual Vivian W. Pinn Symposium

May 11 – 12, 2021